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CHAPTER 1: INTRODUCTION 
Heart failure is a leading cause of mortality in America, accounting for 375,000 
annual deaths (Figure 1.1)1. Heart failure frequently results from coronary artery 
disease with myocardial ischemia in which mitochondrial reactive oxygen species 
(mROS) strongly contribute to cardiac dysfunction2, 3. Notably, mROS are emerging as 
important signaling molecules that strongly influence the sarcomere, which is a key 
structural and functional unit of muscle4. A high level of mROS is a strong contributor for 
cardiac hypertrophy while a low level of mROS regulates calcium signaling and muscle 
contraction5. This complex role of mROS is largely mediated by protein oxidative 
modifications, including glutathionylation that is disulfide bond formation of protein Cys 
residue with intracellular glutathione (GSH)6. However, the identity of proteins that are 
susceptible to glutathionylation in response to mROS and their roles in regulating 
sarcomere stability and integrity remain largely unknown, which is crucial for 
understanding the complex role of mROS in cardiac muscle. 
1.1 The structure of the cardiac muscle 
 Human body contains three major muscles including skeletal, smooth and 
cardiac muscle.   Cardiac muscle forms the wall of the heart and it is a striated muscle 
known as myocardium. Cardiac muscle contains bundles of muscle fibers and 
numerous myofibrils join together to form a muscle fiber. Structural organization of 
Myosin thick and actin thin filaments in myofibrils provides the characteristic striation 
pattern for the cardiac muscle fibers (Figure 1.1a)7.       
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Figure 1.1. Composition and functional subunits in cardiac muscle. (a) 
Organization of cardiac muscle from muscle fibers and myofibrils.  (b) A basic 
contractile unit of striated muscle known as sarcomere which is made up with mainly 
from actin, myosin and titin proteins. Highly organized sarcomere includes several 
important regions including Z line which represents the edges of one sarcomere, M line 
which forms the middle point of sarcomere, elastic I band region which includes mainly 
actin thin filaments and rigid A band mostly comprise with myosin thick filaments. (c)  
Electron micrograph picture of a myofibril. Light color region of sarcomere includes actin 
thin filament and dark color region is an overlap of both actin and myosin filaments. 
Figure adapted from reference (10) with permission from copyright clearance center. 
 
1.2 Sarcomere: the basic contractile unit of the cardiac muscle 
Muscle fiber (myocytes) is composed of linear and cylindrical contractile 
myofibrils that are made of repeated sarcomeres, a basic contractile unit of striated 
muscle8. Sarcomere has a highly organized structure that is assembled by multiple 
sarcomeric proteins, including actin, myosin, and titin (Figure 1.1a). Notably, multiple 
proteins are assembled to form the remarkably regular architecture of sarcomeres. I-
band (light color area in myofibrils) (Figure 1.1b) is an elastic region mostly comprised 
of actin thin filament that alters the sarcomere length during contraction and relaxation9, 
10. Specifically, A-band (dark color area in myofibrils) (Figure 1.1b) is a segment where 
myosin (thick) filaments slide over actin (thin) filaments for contraction. Titin extends 
from Z line to the M line of the sarcomere and interacts with multiple sarcomeric 
proteins in both A-band and I-band for elastic, architectural and signaling function.  Z-
disk forms the border in sarcomere while crosslinking titin and actin filaments (Figure 
1.1a). Alpha actinin is a key structural protein, important for stability of Z disk in 
sarcomere and holds the N terminal region of titin. Myomesin and C-protein are major 
components in M line, a middle point of sarcomere, holds the both myosin thick filament 
as well as C-terminal region of titin protein11. Creatine kinase on M line is important for 
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ATP production by consuming ADP and phosphocreatine while providing energy 
needed for sarcomere shortening or myofibril contraction12.  
1.3 Sarcomere shortening and cardiac muscle contraction  
According to the actin myosin sliding filament theory, when Ca+ concentrations 
increases up to a certain level, Ca+ ions will bind to Troponin and it will induce a 
morphological change in the troponin structure13. This change in shape makes 
tropomyosin move away from the active site of actin. As a result, myosin filaments form 
a cross-bridge with actin.  
 
 
 
 
 
Figure 1.2. Sarcomere shortening caused by Actin myosin sliding filament theory. 
Myosin (thick) filaments (blue) in A band region of sarcomere slide over actin (thin) 
filaments (red) in elastic I band region for contraction. Cellular calcium concentration 
and mitochondrial ATP production is important for this mechanism. Elastic nature of titin 
protein (green) is important for movement of actin filament on rigid myosin filament. 
 
ATP hydrolysis provides enough energy for myosin to bring the actin filament 
inwards and consequently muscle will contract (Figure 1.2). This process occurs on the 
entire myofibril in a muscle cell. Upon the attachment of an ATP molecule to the myosin 
head, actin bound myosin will detach and the cross-bridge will be broken. Upon 
hydrolysis of ATP myosin can reattach to the actin binding site further along the actin 
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filament repeating the continues cycle of “power stroke”14. This is also classified as the 
ratchet mechanism15. This actin movement over myosin will continue until there is an 
enough amount of ATP and calcium16. After the impulse stops, actin comes to its’ 
resting position by lengthening and relaxing the muscle.  
1.4 Intrasarcomeric protein 
1.4.1 Structural features of titin 
Titin, which was initially referred to as connectin, is a giant protein found only in 
cardiac and skeletal muscles. Titin plays an important role in striated muscle action, 
especially in cardiac muscles. Located within the sarcomeres, titin binds to and interact 
with myofilament proteins such as actin and myosin. Therefore, titin is important to 
maintain structure and architecture of the sarcomere by enabling the correct alignment 
of actin and myosin. Also it allows the regulation of the length and distensibility of the 
sarcomere by providing elasticity and this has an impact on both cardiac diastolic and 
systolic functions17. 
Titin is the largest protein found in mammals. The single gene encoding titin has 
363 exons and is located on the long arm of chromosome 2 in the 2q31 region18. There 
are two isoforms of titin found in the heart, which are generated by alternative splicing. 
Isoforms N2B and N2BA vary in size ranging from 2970 and 3700 kDa. Titin has two 
major domains, fibronectin type III-like (called Fn-3 domains) domains and 
immunoglobulin-like (Ig) domains (Ig domains)19. It also has an additional kinase 
domain close to the carboxyl-terminal and several unique-sequence regions. 
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Figure 1.3. Localization of titin within the sarcomere and its domain composition. 
Titin is an intrasarcomeric protein extending from Z-line to M-line and it has a length 
around 1 µm. One titin molecule travel over the four sarcomere zones called M-line 
region, A-band region, I-band region and Z-line region. The amino-terminal is located in 
the Z-line region and carboxyl-terminal of titin is located in the M line of sarcomere. Titin 
protein comprise of several domains including Ig domain, N2 domain and PEVK domain 
are localized in I band region of sarcomere, while largest fibronectin domain is localized 
in rigid A band region. Figure adapted from reference (20) with permission from 
copyright clearance center. 
 
 Titin is an intrasarcomeric protein extending from Z-line to M-line and it has a 
length around 1 µm20. Therefore it can encompass four sarcomere zones called M-line 
region, A-band region, I-band region and Z-line region (Figure 1.3). The amino-terminal 
is located in the Z-line region, whereas the M-line region is in the carboxyl- terminal of 
the protein. In addition to interacting with other proteins in the Z-line, titin is involved in 
intracellular signaling, functioning as a biomechanical sensor (Figure 1.3)21. The A-band 
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region, containing a large proportion of titin protein, has a similar composition in the 
different isoforms (N2B and N2BA). This region of titin is not extensible and it is formed 
by single repeats of Ig and Fn3 domains representing a component that constitutes the 
thick filament. In contrast, the very extensible I-band region provides ability to elongate 
or coil. Therefore it functions as an ''elastic" binding between the thick region and the Z-
line (Figure 1.4)22.  
There are number of structural elements in the I-band region of titin including Ig 
domains, PEVK segment and N2 region (Figure 1.3). The sub-region N2 in I-band 
region can have either N2A or N2B elements creating the two titin isoforms (Figure 
1.4)23. These 2 elements are considered as signaling hubs which are important to 
control the mechanical properties of titin protein and N2A element also important for 
stress-sensing as well. The N2A domain is composed of four immunoglobulin domains 
(Ig80-83, figure 1.4b red) and a unique sequence region, called N2A-Us (also called 
UN2A, figure 1.4b blue), between Ig80 and Ig8124, 25.  
N2A domain interacts with several proteins including MARP family protein 
(CARP, DARP and Ankrd2)26, 27, calpains and calcium dependent proteases28, 29. 
Recently it was found that UN2A region of N2A domain is important for the interaction 
with SMYD2 as well30, 31. The UN2A element contains 106 amino acid residues. The 
N2B element has three Ig domains and a unique 572-residue region. The N2A elements 
are found in both the cardiac and skeletal muscles but the presence of N2B is confined 
only to cardiac muscles.  Both isoforms of titin, N2B and N2BA, are present in cardiac 
muscle32 (Figure 1.5a and b) and N2A isoform of titin 9 (Figure 1.5c) is predominant in 
skeletal muscle33. The smaller N2B isoform is 2970 kDa and has only the N2B element. 
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The larger N2BA consists of both N2B and N2A elements and has a molecular weight 
ranging from 3200 to 3400 kDa (Figure 1.6b). 
 
Figure 1.4. Localization of N2A domain in I band region of sarcomere and its 
domain composition. N2A domain of titin protein is localized in I band region of 
sarcomere and it is considered as a signaling hub which is important to regulate 
mechanical properties of sarcomere. The N2A domain, is composed of four 
immunoglobulin domains (Ig80-83) and a unique sequence region, called N2A-Us (also 
called UN2A), between Ig80 and Ig8134, 35. N2A domain interacts with several proteins 
including MARP family protein (CARP, DARP and Ankrd2) and calcium dependent 
proteases. Recently found that UN2A region of N2A domain is important for the 
interaction with SMYD2 as well. Figure adapted from reference (34) with permission 
from copyright clearance center. 
 
 In humans, both isoforms are present in each half of the sarcomere with a ratio of 
30:70 (N2BA:N2B)36. Due to the presence of an additional extensible element in the I-
band region, N2BA isoform is more distensible and less rigid compared to the N2B 
isoform (Figure 1.5b). This causes increased rigidity in cardiomyocytes expressing high 
levels of N2B isoforms than those that express larger amounts of N2BA isoform37.  
a 
b 
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Figure 1.5. Major titin isoforms. The sub-region N2 in I-band region can have either 
N2A or N2B elements. N2BA contains both N2A and N2B elements and its predominant 
in neonatal cardiac muscle. N2B predominant in adult cardiac muscle and N2A isoform 
of titin is confined only to skeletal muscle. Figure adapted from reference (20) with 
permission from copyright clearance center. 
 
1.4.2 Functional importance of titin 
Titin is the main determinant of passive tension of cardiomyocytes. Due to its 
elastic nature, which is caused mainly due to the I-band region, titin protein involves in 
regulation of the sarcomere length and muscle function. Ig segments, PEVK segments 
and N2 region mainly contribute to elasticity of titin protein (Figure 1.6)38. A complex set 
of events are involved in the development of passive tension during muscle stretching. 
The behavior of different segments in I-band region has different passive tension-length 
relationships. Depending on the sarcomere length, each one stretches at different 
moments. Sarcomeres maintain 1.9 µm long, when titin is in contracted form, during the 
resting state of cardiomyocytes39. During the progressive stretching of the sarcomere Ig 
b 
a 
c 
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sequences are first stretched due to the elongation of the binding between different Ig 
domains (Figure 1.6). At 2.15 µm the PEVK segments start elongating, followed by the 
N2 segments (Figure 1.6)40. 
 
Figure 1.6. Mechanism of sarcomere elongation. Titin protein involves in regulation 
of sarcomere length and muscle function. Ig segments, PEVK segments and N2 region 
are mainly contributed to elasticity of titin protein to facilitate the myofibril contraction 
and relaxation. Figure adapted from reference (20) with permission from copyright 
clearance center. 
 
1.4.3 Structural and functional importance of SMYD2 
SMYD2 is one of the SET and MYND-containing lysine methyltransferases 
(SMYD). SMYD is a family of five members which includes SMYD (1-5) (Figure 1.7a 
and b)41. Catalytically important SET domain of SMYD family catalyzes the mono 
methylation of protein lysine residues using S-adenosylmethionine (SAM) as the methyl 
donor and release the S-adenosylhomocysteine (SAH) as a byproduct (Figure 1.7c). 
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Cysteine-rich zinc finger containing MYND domain was initially found in Myeloid 
translocation protein 8, Nervy, and DEAF-1. This domain is mainly important for protein- 
protein interaction and it shows a preference towards the proteins with a proline rich 
motif41.  
 
 
Figure 1.7. Domain organization and catalytic activity of SMYD2. (a) Ribbon 
diagram of SMYD2 protein with SAH molecule in catalytically important SET domain 
(PDB = 3QWV). (b) Schematic presentation of SMYD family and their domain 
composition. Catalytically important SET domain (green), MYND domain which is 
important for protein-protein interaction (blue) and C-terminal region with TPR domain 
(red). (c) Mono methylation of lysine residues catalyzes by SMYD protein using SAM as 
the methyl donor and production of SAH as the byproduct. Figure adapted from 
reference (41) with permission from copyright clearance center. 
 
C-terminal region of SMYD1-4 has a tetratricopeptide (TPR) like domain which is also 
involved in protein-protein interactions and HSP90 mainly binds to the TPR domains of 
c 
a b 
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SMYD2 (Figure 1.7b)41, 42. SMYD2 has 17 cysteine residues, ten of which are bound to 
three zinc ions in the MYND and Post-SET domains. SMYD2 is mostly cytoplasmic43 
where it catalyzes mono-methylation of p53 to suppress apoptosis44, retinoblastoma 
protein (pRb) to enhance cell cycle progression45, estrogen receptor α (ERα) to 
suppress its transactivation46,  and heat shock protein 90 (Hsp90) to enhance its 
chaperone activity and cell proliferation47.  Recent proteomic analysis found over 200 
substrate proteins, suggesting its roles in diverse cellular processes48. 
1.4.4 Importance of SMYD2 for sarcomere integrity 
Importantly, both SMYD1 and SMYD2 are abundant in cardiac and skeletal 
muscle, playing an important role in myofibril assembly. SMYD1 is important for heart 
development49. Thus, SMYD1 null mice embryos do not survive due to failure in right 
ventricle formation of heart50. On the other hand, an early study showed that cardiac 
SMYD2 knockout mice have no detrimental effect on heart development, suggesting 
that SMYD2 is dispensable for heart development51. But, recently mice with conditional 
knockout of SMYD2 showed an enhanced level of cardiomyocyte apoptosis upon 
myocardial infarction by proving its cardioprotective function in pathophysiological 
conditions of heart muscle52. Recently, it was found that zebrafish with SMYD2 
knockdown forms a disorganized I-band and Z-disks in sarcomere in heart and skeletal 
muscle, suggesting its potential role in sarcomere organization or stabilization31. 
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Figure 1.8. Protein complex of SMYD2: HSP90: N2A domain on sarcomere and 
binding surfaces of SMYD2 and N2A domain. (a) In a molecular level, SMYD2 forms 
a complex with Hsp90. This complex binds to N2A domain of titin at I-band of 
sarcomere. UN2A region of N2A domain is important for the interaction with SMYD2 (b) 
ribbon diagram of SMYD2 with cysteine 13. N-terminal region (11-30 aa) and C-terminal 
region (424-433 aa) of SMYD2 are important to interact with the N2A domain of titin 
protein. Figure adapted from reference (20) with permission from copyright clearance 
center. 
a 
b 
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 In myocytes, SMYD2 is involved in mono-methylation of Hsp90, which increases 
Hsp90 chaperone activity. SMYD2 then forms a complex with mono-methylated Hsp90 
(Figure 1.8a). This complex binds to N2A, a domain of titin, which has been implicated 
to be important for sarcomere stabilization31. The N2A domain is composed of four 
immunoglobulin domains (Ig80-83, figure 1.8a red) and a unique sequence region, 
called N2A-Us (also called UN2A, figure 1.8a blue), between Ig80 and Ig81 (Figure 
1.8a). UN2A region of N2A domain is important for the interaction with SMYD230. N-
terminal region (11-30 aa) and C-terminal region (424-433 aa) of SMYD2 are important 
to interact with the N2A domain of titin protein (Figure 1.8b). SMYD2-methyl HSP90-
N2A complex has shown to be important for sarcomere organization especially in I-band 
region (Figure 1.8a).  Notably, SMYD2 knockdown decreases the level of N2A (a 
domain of titin) and induces disorganization of sarcomere structure in zebrafish, 
showing the importance of SMYD2 for the integrity and stability of sarcomere31.  
1.4.5 Importance of α-actinin for sarcomere integrity 
ᾳ-Actinin belongs to a family of actin binding proteins and a part of the spectrin 
superfamily which includes two other major proteins known as spectrin and 
dystrophin53. Alpha actinin is important for cytoskeleton framework in non-muscle cells 
and it is a key structural protein important to stabilize the Z-disk of sarcomere in striated 
cardiac and skeletal myocytes (Figure 1.9). Alpha actinin forms a lattice like structure at 
the Z-disk and supports the contractile nature of sarcomere (Figure 1.9)53. The ABD 
domain of alpha actinin holds the antiparallel actin filaments to support the filament 
sliding mechanism between the actin and myosin. Meanwhile a CaM like domain of 
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muscle related α-actinin interacts with the Z-repeats on N-terminal region of titin protein 
in striated muscle54.   
 
 
Figure 1.9. Localization of alpha actinin in Z-disk of sarcomere. Alpha actinin (red 
color), actin filament (pale blue color), titin (ash color). The α-actinin maintains the 
interaction between antiparallel actin filaments and holds the N-terminal region of titin 
protein. Figure adapted from reference (53) with permission from copyright clearance 
center. 
 
1.4.6 Structural and functional importance of troponin 
A basic contractile unit in striated muscle (sarcomere) includes two filaments 
known as myosin thick filament and actin thin filament. F-actin and G-actin combination 
forms the actin thin filament. Troponin complex made of troponin C, troponin T and 
troponin I is localized on the groove of the F-actin filament interacting with the 
tropomyosin protein (Figure 1.10a)55. Mainly, intracellular calcium concentration 
regulates the muscle contraction and relaxation. Binding of calcium onto troponin 
complex triggers the muscle contraction (Figure 1.10b).  
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During relaxation period, tropomyosin blocks the accessibility of myosin head into active 
site of actin in order to generate the muscular force. Binding of calcium to TnC produces 
structural changes in TnI and disrupt the interaction between actin thin filament and 
tropomyosin (Figure 1.11b)56. Disruption of this complex facilitates the interaction 
between myosin head and actin active site in order to produce the muscle contraction or 
shortening of sarcomere57. In addition to involvement in muscle contraction and 
relaxation, troponins are considered as a biomarker in cardiac muscle disorders 
including myocardial infarction, heart failure and cardiomyopathy55. 
 
a 
b 
17 
 
Figure 1.10. Localization and functional importance of troponins. (a) Localization of 
troponin complex in groove of the actin thin filament. (b) During muscle relaxation 
tropomyosin blocks the active site of actin (blue color dots on actin filament are covered 
by brown color tropomyosin). Calcium binding to TnC induces disruption of tropomyosin 
and actin filament complex (blue color dots are exposed to myosin heads) while 
facilitating myosin: actin interaction in order to activate the muscle contraction. Figure 
adapted from reference (56) with permission from copyright clearance center. 
 
1.5. Mitochondria is important for cardiac metabolism 
Mitochondria are one of the major organelles which govern the lifetime of cardiac 
myocytes. Healthy cells of the beating heart meet their high energy demand by the ATP 
derived from mitochondria via oxidative phosphorylation. Thus, mitochondria often 
categorized as the “Powerhouse of the cell”. This highly efficient and localized supply of 
ATP helps to sustain basic functions such as metabolism, contraction and ion 
homeostasis in cardiac myocytes (Figure 1.11). Mitochondria are primarily localized in 
between the myofibrils and below the sarcolemma in each myocyte. Furthermore, it 
plays a vital role in regulating apoptosis in response to stress signals such as hypoxia 
and oxidative stress (Figure 1.11)58.   
1.5.1 Mitochondria are the major energy source in cardiac muscle 
Energy-demanding cardiac tissues are rich in mitochondria accounting for 20-
40% of cellular volume. Energy production in mitochondria depends on several factors 
including enzyme activity, availability of cofactors, oxygen and fuels such as sugars and 
fatty acids (Figure 1.11)58. Number of bioenergetic pathways contributes to energy 
production in mitochondria. They include pyruvate oxidation, the tricarboxylic acid (TCA) 
cycle, the mitochondrial β-oxidation of fatty acids and oxidative phosphorylation.   
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Figure 1.11. Mitochondrial behavior in physiological and pathological conditions 
of cardiac muscle. In physiological conditions where sufficient level of glucose, fatty 
acid and oxygen are present, mitochondria produce satisfactory level of ATP molecule 
to facilitate the muscle contraction and relaxation. In pathological conditions depletion of 
nutrition and oxygen result higher level of ROS production through dysfunctional 
mitochondria.  When antioxidant capacity coming from NADPH (electron carrier) or 
redox enzymes may not be able to counteract the effects of ROS creates an oxidative 
stress in-vivo.  Myocardial stress lowers the ATP production and activates the proteases 
including calpain and MMP-2 which are involved in sarcomeric protein degradation. 
Degradation of proteins in sarcomere affects the myofibril integrity and cardiac muscle 
contraction. 
 
 About 80-90% of cellular ATP is produced by oxidative phosphorylation occurring 
in the proteins at the mitochondrial inner membrane including complexes I-IV, ATP 
synthase (complex V) and adenine nucleotide translocator (ANT). In cardiac muscles, 
ATP is generated primarily by fatty acid β-oxidation59. In normal cardiac tissue, there is 
limited ATP supply from other sources such as glycolytic metabolism. Several transport 
proteins are required to efficiently transport fatty acids into cardiomyocytes and then into 
mitochondria. The major sources of electrons for the electron transport chain are the 
intramitochondrial NADH and FADH. They are generated primarily by fatty acid β-
oxidation and the oxidation of carbohydrates via the TCA cycle. Additionally, the heart 
stores high energy phosphates such as phosphocreatine which is produced by 
mitochondrial creatine kinase using ATP60.  
1.6 Ischemia-reperfusion induces mitochondrial ROS production 
Complex I and complex III in mitochondria convert about 0.2-2% of molecular 
oxygen into superoxide during cellular respiration which is important to synthesize an 
energy molecule “ATP”. Therefore mitochondria are considered as a major source of 
ROS in intracellular environment. During mitochondrial electron transfer, O2 captures an 
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electron from Complex I or from the ubisemiquinone located in Complex III and produce 
superoxide (Figure 1.11)61.  
 Myocardial ischemia, obstruction of a blood flow caused by a plaque in coronary 
arteries prevents the supply of both nutrition and oxygen into the heart muscle. Low 
level of oxygen as well as nutrition affects the metabolism of cardiomyocytes by 
lowering the capacity of oxidative phosphorylation and mitochondrial ETC flux60, 62. 
Furthermore, upon depletion of creatine phosphate levels, impaired oxidation of fatty 
acids and pyruvate along with reduced ATP production can also be seen. Accumulation 
of lactate during breakdown of ATP derived via TCA cycle leads to drop of intracellular 
pH causing acidosis which has a direct effect on the contractile function of cardiac 
muscle61. 
In reperfusion conditions, where there is a high oxygen concentration, 
mitochondrial ROS production is elevated. Also increased level of superoxide occurs 
when there is a reduction in Complex I activity. In cardiac muscles there is a high 
density of mitochondria and during ischemia-reperfusion injury significant amount of 
superoxide is produced due to high rate of oxidative phosphorylation (Figure 1.12)63. 
Moreover, at the onset of reperfusion, mitochondria can aggravate the ischemic 
damage. During reperfusion, high acetyl CoA levels can form via increased fatty acid 
intake and unregulated fatty acid oxidation thus saturating the TCA cycle. This 
eventually causes an inhibition of the glycolysis and pyruvate oxidation. Furthermore, 
increase of OXPHOS tends to accumulate more ROS with respect to elevated levels of 
lipid peroxidation (Figure 1.12)64.  
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In general, there are antioxidant enzymes in mitochondria to detoxify superoxide 
by converting it to water and oxygen. They include manganese superoxide dismutase 
(MnSOD), catalase, and glutathione peroxidase (GPx). But when these antioxidant 
systems fail to neutralize excess amounts of ROS, oxidative stress occurs inside the 
cell (Figure 1.11)4. 
1.6.1 Antimycine A induces mROS production 
Complex I and complex III in mitochondria are known to produce superoxide from 
molecular oxygen during cellular respiration. Complex I is localized in the inner 
membrane of mitochondria and it is known to be the entry point of electron carriers. 
During cellular respiration, ROS production in complex I will be minimal but, binding of 
rotenone, inhibitor of complex I, generates ROS production by blocking the electron 
transfer from ion-sulfur center to the CoQ site65. Complex III is also localized in inner 
membrane of mitochondria and is important for transfer electron from CoQH2 to 
cytochrome c (Figure 1.12)66. Antimycin A is a known inhibitor of complex III and 
produces ROS by blocking the shuttle of electron from QO site to QI site by binding to Qi 
site. Blockage of electron transfer at complex III67 induce ROS production through 
superoxide generation by molecular oxygen (Figure 1.12)68. But, during physiological 
conditions, superoxide generation by complex III will be minimum.     
1.7 ROS induce oxidative stress 
Having unpaired electrons in the outer orbit, reactive oxygen species such as 
superoxide (O2
-.), peroxynitrite (ONOO.-) and hydroxyl radicals (•OH) are highly reactive. 
O2
-. is generated  through reduction of molecular O2 by one electron. Due to its poor 
membrane permeability, it has a limited capacity to diffuse and therefore generally 
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restricted to intracellular compartments where it is produced. The half-life of O2
-.
 is only a 
few seconds as it is rapidly dismutated to H2O2 and oxygen . 
 
 
Figure 1.12. Antimycin A induces mROS production by blocking complex III in 
mitochondria. Antimycin A is a known inhibitor of complex III and produces ROS by 
blocking the shuttle of electron from Q0 site to Q1 site by binding to Qi site. Blockage of 
electron transfer at complex III, induce ROS production through superoxide generation 
by molecular oxygen. Figure adapted from reference (67) with permission from 
copyright clearance center. 
 
 But H2O2 is more stable and membrane permeable
69. Therefore it can act at 
more remote sites. •OH is the most reactive oxygen free radical and it is formed from 
H2O2. In normal cells the level of 
•OH is negligible. But in pathological conditions such 
as ischemia-reperfusion, there is an elevated level of •OH. This may contribute to 
cellular damage associated with oxidative stress. ONOO.- is produced when O2 reacts 
with NO. This occurs at high nanomolar range of NO and results in its inactivation 
(Figure 1.13)70.  
There are number of potential sources of ROS in major cardiac cell types; 
cardiac myocytes, fibroblasts and endothelial cells71, 72. They include mitochondrial 
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respiratory chain72, NADPH oxidases73, xanthine oxidase (XO)74, NO synthases75, 
lipoxygenase76, peroxidases, cytochrome P-450s and other hemoproteins77. Among 
these sources, mitochondria, NADPH oxidases and XO are considered as major 
contributors to heart failure (Figure 1.13).   
 
 
Figure 1.13. ROS sources and species contribute to oxidative stress. Imbalance 
between antioxidant defense system and ROS generation cause oxidative stress78. 
Numerous ROS and RNS species including superoxide, hydrogen peroxide, nitric oxide 
and peroxynitrite contribute for myocardial stress induce by ischemia/ reperfusion injury. 
Dysfunctional mitochondria, NADPH oxidase, xanthine oxidase and uncoupled nitric 
oxide synthase are major sources of ROS and accumulation of  these reactive molecule 
cause cardiac muscle dysfunction and heart failure78. Figure adapted from reference 
(78) with permission from copyright clearance center. 
 
There are number of enzymatic and non-enzymatic pathways in normal cells to 
counterbalance these ROS. Superoxide dismutases (SODs), glutathione peroxidase 
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and catalase enzymes are the major endogenous antioxidant pathways79. SOD 
converts O2
-.
 into H2O2 and oxygen. Several different SOD enzymes are present in 
different cellular compartments. Manganese SOD (Mn SOD), copper/zinc (Cu/Zn) SOD 
and extracellular SOD are present in mitochondria, cytosol and plasma membrane 
respectively. By converting H2O2 to water and O2 , cellular catalases and glutathione 
peroxidase maintain the H2O2 levels in the cells where glutathione acts as a reducing 
substrate during the enzymatic activity of glutathione peroxidase80. Another important 
antioxidant defense is provided by thioredoxin and thioredoxin reductase; they catalyze 
generation of ubiquinone (Q10), ascorbic acid and lipoic acid which are antioxidant 
molecules81. These and other intracellular antoioxidants including vitamins E, C and β-
carotene, urate and glutathione provide non-enzymatic mechanisms to counter balance 
ROS82.  But, the imbalance between this antioxidant capacity and ROS generation 
cause an oxidative stress in intracellular environment.  
1.8 Oxidative stress induce protease activation 
It is emerging that a highly ordered structure of sarcomere is maintained in a 
dynamic process that involve an intricate balance between assembly and degradation of 
sarcomeric proteins by the action of many chaperones and proteases. In particular, an 
ischemia-reperfusion injury leads to an increased activity of several proteases, including 
matrix-metalloprotease 2 (MMP-2) and calpain 1/3 (Figure 1.14)83. Activated MMP2 is 
involved in degradation of several sarcomeric proteins, including titin, α-actinin, 
troponin, and myosin-light chains84, 85. Activated calpain is also responsible for 
degradation of titin and troponin. 
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Figure 1.14. Sarcomere associated protease activation by ischemia-reperfusion 
injury. Dysfunctional mitochondria cause higher level mROS production and 
accumulation of intracellular calicium. Oxidative stress induce protein glutathionylation 
activates MMP2 and overload of calcium cause by malfunction of ion-channels activates 
calcium dependent calpain protease.  
 
 1.8.1 Structural features and functional importance of MMP-2 
MMP-2 is a zinc-dependent protease involved in cardiac remodeling and has 
shown its increased activity during myocardial ischemia and reperfusion injury. Mainly, 
MMP-2 is localized on I band region of sarcomere (sarcomeric MMP-2) and two other 
forms known as cytoskeletal and nuclear MMP-286 has been reported. It includes 
several domains including N-terminal signal sequence (Pre domain), propeptide 
domain, catalytic site with zinc ion binding site, and C-terminal haemopexin domain 
(Figure 1.15a). A cysteine amino acid in the highly conserved PRCGVPD sequence 
within the auto inhibitory pro-peptide domain prevents the accessibility of substrate by 
making an interaction with a catalytically important zinc ion85.  Because of this, MMP-2 
is considered as a latent enzyme which can be activated by either oxidative stress or 
proteolytic cleavage. Oxidative stress induces S-glutathionylation of critical cysteine 
residue in the pro-domain, disrupts the interaction between thiolate and zinc ion 
resulting an active full length MMP2 enzyme (Figure 1.15b). Active MMP-2 plays a role 
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in sarcomeric protein degradation87. Meanwhile, activation of MMP2 involves in 
myocardial apoptosis via activation of β-adrenergic receptors. MMP-2 mediated 
regulation of poly (ADP-ribose) polymerase (PARP) or glycogen synthase kinase-3b 
(GSK-3β) are involved in cardiomyocyte apoptosis (Figure 1.15c)88. 
 
 
 
a 
b 
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Figure 1.15. Composition and activation of MMP-2. (a) Schematic presentation of full 
length (72 kDa) and proteolytically cleaved MMP-2 (64k Da). (b) Activation of full length 
MMP2 by glutathionylation under oxidative stress conditions. Proteolytic cleavage of 72 
kDa MMP2 by MMP-14 and tissue inhibitor of metalloproteinase-2(TIMP-2) to produce 
active 64 kDa MMP-2. (c) Active MMP-2 degrades sarcomeric protein including MLC-1, 
TnI and α-actinin. MMP-2 plays a role on cardiomyocyte apoptosis through regulation of  
PARP or GSK-3β85. Figure adapted from reference (85) with permission from copyright 
clearance center. 
 
1.8.2 Structural features and functional importance of calpain 1 
Calpain is a cysteine protease which is dependent on calcium ion availability for 
its activation and mostly localized on cytoplasm89. Mainly, there are two conventional 
calpains in mammalian cells which differ by the calcium sensitivity. One is μ-calpain 
sensitive to µM concentrations of calcium and m-calpain needs mM concentration of 
calcium for its activation.  There are two major domains in calpain including 80 kDa 
catalytic subunit and 30 kDa regulatory subunit. Disruption of calpains into subunits in 
the presence of calcium results in the substrate cleavage by 80 kDa catalytic subunit 
c 
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(Figure 1.16a)90. Oxidative stress or mitochondrial damage negatively regulates calcium 
homeostasis, and the resulting calcium overload activates cellular calpains. Cleavage of 
calpastatin, p35 or calcineurin leads to induction of apoptosis through caspase 
activation (Figure 1.16b)91, 92.  
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Figure 1.16. Composition and activation of calpain 1. (a) Schematic presentation of 
80 kDa catalytic subunit and 30 kDa regulatory subunit. (b) Impairs calcium 
homeostasis cause by oxidative stress and mitochondrial damage leads to calpain 
activation. Active calpain degrades calpastatin, p35 or calcineurin to activate caspase 
which involves in apoptosis91. Figure adapted from reference (91) with permission from 
copyright clearance center. 
 
1.9 Protein S-glutathionylation 
High level of reactive oxygen/nitrogen species (ROS/RNS) or failure in 
antioxidant defenses in the cells cause oxidative stress due to changes in cellular 
homeostasis. This can cause reversible or irreversible damage to proteins when they 
undergo oxidative modifications. Specifically, the thiol groups in proteins are more 
susceptible to oxidative modifications in response to changes in cellular ROS/NOS 
levels. Cysteine is an amino acid with nucleophilic sulfhydryl group, found in active sites 
of proteins and plays an important functional role.  
 
Figure 1.17. Protein thiol oxidative modifications.  A Reaction between a reactive 
thiol and ROS produces a sulfenic acid moiety which can be further modified by GSH to 
make the glutathionylated proteins.  Redox enzymes or reducing agents restores the 
protein thiol by reducing the glutathionylated protein.  Higher level of oxidative stress 
can further modify these sulfenic acids into sulfinic or sulfonic moieties which are 
30 
 
recognize as irreversible modification. The consequences of this irreversible protein 
modification include inactivation of the protein as well as degradation of the protein. 
 
 When a functionally important cysteine sulfhydryl group is modified, this can 
affect the protein activity93. Even if the cysteines are not in the active site, oxidative 
modifications can cause conformational changes in the protein and its activity94. 
However, in the cells, there are mechanisms which reverse the redox alterations in 
protein thiols. Glutathionylation is one such important mechanism to regulate protein 
oxidation.          
1.9.1 Mechanism of protein S-glutathionylation 
Maintaining an optimal GSH/GSSG ratio in the cell is essential to regulate the 
redox state of protein thiols and continue cell survival. In physiological conditions, the 
cell has a reducing environment with a GSH/GSSG ratio around 10095. Changes in this 
ratio can cause oxidation of protein cysteinyl residues and therefore even a slight 
shifting of this equilibrium could promote protein S-glutathionylation. There are several 
ways protein glutathionylation can occur including direct interaction between GSH and 
partially oxidized cysteine thiols in proteins (sulfenic acid moieties or S-nitrosothiol)96, 
thiol/disulfide exchange reactions between oxidized glutathione and thiol groups in 
proteins, and reaction between S-nitrosoglutathione (GSNO) and protein reactive thiols 
(Figure 1.17)97, 98. In addition, glutathione sulfenic acid and glutathione disulfide S-
monoxide can contribute for protein glutathionylation99. 
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1.9.2 Cycle of protein S-glutathionylation 
 Glutathione S-transferases (GST’s) are a class of enzymes which mediate 
enzymatic formation and removal of S-glutathionylation. They decrease the pKa of thiol 
group in GSH and therefore increase its nucleophilicity and the reactivity promoting S-
glutathionylation. One of the GST family members, GSTP, is known to increase 
glutathionylation in specific substrates such as peroxiredoxin100, 101. When the catalytic 
cysteine in peroxiredoxin is oxidized to sulfenic acid, its peroxidase activity is inhibited. 
But S-glutathionylation of the active site cysteine mediated by GSTP restores the 
catalytic activity102.  
 
 
Figure 1.18. Redox enzymes induce Protein glutathionylation and 
deglutathionylation. Glutathione S-transferases (GST’s) are a class of enzymes which 
mediate enzymatic formation and removal of S-glutathionylation. GSTP1 known to 
involve in protein glutathionylation and GSTO1 mainly catalyze deglutathionylation of 
proteins. Oxidation of Grx1 also involves in protein deglutathionylation. Oxidation of 
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GSH reduces oxidized Grx1 and GSTO1 enzymes. Meanwhile GR brings oxidized GSH 
back to reduced form by consuming NADPH which is a well-known electron carrier 
important to maintain the redox potential in-vivo. 
 
 
 There are several other enzymes which play a role in S-glutathionylation such as 
glutaredoxin 1 (Grx1)103, glutaredoxin 2 (Grx2) and gamma-glutamyl transpeptidase. 
Grx catalyzes glutathionylation of many proteins including GAPDH, actin and protein-
tyrosine phosphatase 1B (PTP1B)104. On the other hand, Grx has a role in 
deglutathionylation of proteins by catalyzing the removal of GSH from cysteine residues 
by disulfide-exchange mechanism (Figure 1.18). The Grx-catalyzed deglutathionylation 
involves both monothiol and dithiol mechanisms and release of GSSG which is reduced 
back to GSH by GR (Figure 1.18). There are several other enzymes involved in 
deglutathionylation. Sulfiredoxin (Srx) deglutathionylates many proteins, such as PRX1, 
actin and PTP1B104. Deglutathionylation of catalytic cysteine in PTP1B activates its 
phosphatase activity and therefore plays a crucial role in regulating important signaling 
pathways103. 
1.9.3 Regulation of protein function through S-glutathionylation 
When cells undergo oxidative stress, the thiol groups in proteins can get oxidized 
into sulfinic and sulfonic acids. The consequences of this irreversible protein 
modification include inactivation of the protein as well as degradation of the protein105, 
106Therefore under oxidative stress, where there is a high level of ROS or RNS 
production, protein S-glutathionylation plays an important role in protecting the protein 
thiols from permanent oxidation. This may also has a regulatory function in different 
cellular processes as evident by the glutathionylation of cysteines in some proteins even 
at basal conditions102.  
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Since S-glutathionylation is reversible, it enables the restoration of protein 
function by reducing the protein thiols back to the native sulfhydryl form107. As 
examples, reversible inactivation of γ-glutamyl transpeptidase, α-ketoglutarate 
dehydrogenase and HDL-associated paraoxonase 1 (PON1)108 by S-glutathionylation 
protect these enzymes from irreversible oxidative damage caused by oxidative stress 
including hydrogen peroxide, alterations in mitochondrial GSH status etc109.     
 Nevertheless, modification of a functionally critical cysteine by S-
glutathionylation may affect the protein function and compromise its cellular activities, 
especially in the case of enzymes and transcription factors110. Also it can effect 
ROS/RNS production and is evident in Cu/Znsuperoxide dismutase, thioredoxin, 
glutaredoxin and 1-Cys peroxiredoxin when they undergo S-glutathionylation111-113.  In 
some instances, protein function is inhibited by glutathionylation as seen with some of 
the metabolic enzymes, including tyrosine hydroxylate, aldose reductase, creatine 
kinase and GAPDH114.   
 Glutathionylation of different cysteine residues in the same protein can have 
different biological significances. When Cys67 in HIV-1 protease is glutathionylated, it 
stabilizes the protein and activates protease activity. In contrast, glutathionylation of 
Cys95 is involved in inhibiting the protease activity. As another example, in carbonic 
anhydrase III, glutathionylation of Cys186 activates its phosphatase activity whereas 
Cys181 glutathionylation inhibits it.   
 S-glutathionylation regulates many kinases and phosphatases and therefore it 
plays an important role in cellular signaling pathways during cell proliferation, 
differentiation, apoptosis and immunity115. S-glutathionylation of Ras, a small GTPase is 
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induced by angiotensin II and is involved in hypotrophy in both smooth muscles and 
cardiac myocytes116. Glutathionylated Ras activates downstream signal transduction 
pathways involving ERK and AKT, and also inhibits insulin signaling in endothelial 
cells117. S-glutathionylation can inhibit most of the kinases118. For instance, when 
Cys199 in the active site of protein kinase A (PKA) undergoes glutathionylation, the 
kinase activity is inhibited in a reversible manner119. Protein glutathionylation can 
regulate several transcription factors by altering protein-DNA interactions. 
Glutathionylation of p65 and p50 subunits in NF- kB interferes with DNA binding and 
therefore inhibits transcription of target genes120.  
 Previous studies have shown ROS induced oxidative modifications of several 
sarcomeric proteins99. Myosin heavy chain is oxidized at C697 and C707, which reduce 
its ATPase activity, thus decreasing the sliding force during sarcomere contraction121. 
Actin is glutathionylated at C374, which decreases the maximum contractile force122. 
Titin is glutathionylated at cryptic cysteine residues or oxidized at N2B domain, which 
decreases sarcomere elasticity and increases stiffness of sarcomere during 
contraction123. Previous global analysis found relatively a few number of proteins (e.g. 
actin, tropomyosin, and troponin) glutathionylated in sarcomere, muscle, or myocytes124. 
However, the identity of proteins that are susceptible to glutathionylation in response to 
mROS and their roles in regulating sarcomere stability and integrity remain largely 
unknown, which is crucial for understanding the complex role of mROS in muscle. 
1.10 Clickable glutathione approach in cardiomyocyte cell line 
A direct consequence of ROS in the sarcomere includes oxidative protein 
modifications, including disulfide, sulfenylation, and glutathionylation.125, 126 In particular, 
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glutathionylation is one of the significant oxidative protein modifications in response to 
ROS.127 We recently developed a clickable glutathione approach to identify protein 
glutathionylation.128, 129 In this approach, we mutated one of the enzymes involved in 
glutathione biosynthesis pathway. The γ-glutamylcysteine synthetase, the first and rate 
limiting enzyme, catalyzes the reaction between glutamic acid and cysteine in order to   
synthesize the γ-glutamylcysteine (Figure 1.19). Glutathione synthetase, the second 
enzyme of GSH biosynthesis pathway, catalyzes the reaction glycine with γ-
glutamylcysteine to produce GSH (γGlu-Cys-Gly) in-vivo (Figure 1.19a)130, 131.  
Azido-glutathione (γGlu-Cys-azido-Ala) is in situ biosynthesized in cells 
expressing a glutathione synthetase mutant (GS M4) that efficiently catalyzes an 
incorporation of azido-Ala in place of Gly in glutathione (γGlu-Cys-Gly) (Figure 
1.19a).128  
 
 
a 
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Figure 1.19. Clickable glutathione approach in H9c2 myocytes to detect protein 
glutathionylation. Mutant form of a glutathione synthetase, second enzyme of 
glutathione biosynthesis pathway, catalyzes the incorporation of azido alanine onto γ-
glutamylcysteine more effectively than glycine synthesizes a glutathione derivative in 
vivo with a azido clickable handle. During oxidative stress (ROS stimuli) labeled proteins 
with clickable glutathione detects by in-gel fluorescence (global protein 
glutathionylation) or biotin-streptavidin analysis (individual protein glutathionylation).   
 
Importantly, a clickable functionality on glutathione serves as an efficient 
chemical tag for identifying and characterizing glutathionylated proteins. During 
oxidative stress (ROS stimuli), labeled proteins with clickable glutathione (global protein 
b 
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glutathionylation) are detected by in-gel fluorescence analysis using a fluorophore 
alkyne and individual protein glutathionylation can be detected by streptavidin-biotin 
pulldown (Figure 1.19b). 
With this approach, we recently found that glucose depletion or a treatment of 
mitochondrial electron transport chain blockers strongly induces global protein 
glutathionylation in which glucose availability was an important factor for induction of 
glutathionylation.132 Further mass spectrometry analysis identified multiple 
glutathionylated proteins, including SET and MYND domain-containing protein 2 
(SMYD2).132 
1.11 Specific goals and significant findings of the dissertation work 
ROS play an essential role in redox signaling, but also cause detrimental effects 
under oxidative stress, especially in cardiac and skeletal muscle133. For example, low 
levels of ROS are produced in muscle or increased during exercise, regulating 
intracellular calcium release and contractile force134. Hydrogen peroxide (H2O2) derived 
from the endothelium and myocardial mitochondria serves as a vasodilator that 
regulates the coronary collateral flow135. In contrast, high levels of ROS induce 
abnormal calcium regulation, a loss of contractile force, contractile dysfunction, and 
hypertrophy.  Indeed, elevated levels of ROS are associated with muscle-related 
pathological conditions, including myocardial ischemia-reperfusion injury136, heart 
failure71, and muscular dystrophy137. 
The basic contractile unit of striated muscle is a sarcomere. Sarcomeres are 
composed of multiple sarcomeric proteins, including actin, myosin, and titin, that are 
assembled in a highly organized structure8. Many of these ROS effects partially result 
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from oxidative modifications of sarcomeric or myofibrillar proteins. For example, ROS 
elevated during ischemic reperfusion cause glutathionylation and carbonylation of 
actin138, glutathionylation of troponin subunits139, and disulfide formation in 
tropomyosin140, nitration of myosin141, many of which result in the reduced contractile 
force of myofilaments. Titin is also oxidized in multiple regions. For example, the N2B 
domain of titin forms disulfide, which increases muscle stiffness142. The cryptic cysteine 
residues in Ig-domains of titin at the I-band are also glutathionylated, which reduces 
passive stiffness123. 
 One major consequence of ischemic reperfusion injury that induces 
mitochondrial ROS or during autophagy under nutrition-deprivation is degradation of 
sarcomeric proteins, which reduces the contractile force of muscle143-145. For example, 
an ischemia-reperfusion injury leads to an increased activity of several proteases, 
including MMP-2 and calpain 1/383.  Activated MMP-2 and calpains are involved in 
degradation of several sarcomeric proteins, including titin, α-actinin, troponin, and 
myosin-light chains84, 85. In particular, titin serves as an integral part for a stress-sensing 
network. The elastic region of titin binds with chaperones, proteases, and signaling 
complexes of which interactions are altered in response to the mechanical and chemical 
stress, ultimately causing muscle degradation, remodeling or adaptation to stress3, 146. 
The molecular link between sarcomeric protein oxidative modification and the action of 
the protease system is not well-characterized. In order to address these unanswered 
questions, I started to analyze the functional importance of SMYD2 glutathionylation in 
cardiomyocytes as my dissertation work. 
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 Glutathionylation plays an important role in regulating protein function in cellular 
stress127. In this report, we used our clickable glutathione approach to detect 
glutathionylation of multiple proteins, including SMYD2, under stressed conditions. A 
key idea of our approach is routing glutathione biosynthesis to clickable glutathione by 
using a mutant of a glutathione biosynthetic enzyme147. A modified clickable glutathione 
is an efficient substrate of glutathione disulfide reductase (GR), glutathione transferase 
omega (GSTO), and glutaredoxin 1 (Grx1), and is tolerated in cells without significant 
disturbance of the redox system129, 148, all of which support that our approach is suitable 
for investigating glutathionylation in response to cellular stress.  
 We confirmed glutathionylation of SMYD2 in various stressed conditions and 
found selective glutathionylation at Cys13. While there are 17 Cys residues in SMYD2, 
many of them are bound to zinc atoms or buried inside SMYD2, thus may not be 
accessible for glutathionylation.  
 A key observation in my dissertation is that myofibril integrity is significantly lost 
in cells expressing SMYD2 WT in response to ROS, whereas SMYD2 C13S protects 
myofibrils from degradation, showing a critical role of SMYD2 glutathionylation in 
myofibril integrity or sarcomere stability.  
 Another important finding is that protein interaction between SMYD2 and the N2A 
domain of titin contributes to modulating myofibril or sarcomere degradation. Indeed, 
protein-protein interactions at titin’s extensible domains, including N2B, PEVK, and N2A 
at the I-band, play a central role in stress-signaling149. The N2A domain has four Ig-
domains and one extensible unique sequence (N2A-Us) 150. Hsp90-SMYD2 chaperone 
complex binds to N2A, mainly with N2A-Us.  Our data showed that the SMYD2-N2A 
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interaction protects N2A from degradation by MMP-2 and calpain 1, and SMYD2 also 
protect titin in myofibrils from MMP-2 mediated cleavage. 
  Therefore, our data support the concept that N2A is an important domain of titin 
where the SMYD2-Hsp90 chaperone complex interacts for stabilization or protection of 
sarcomeres. Notably, it is interesting to find that N2A can be cleaved by MMP-2 and 
calpain 1 in our data. While titin is known to be degraded by MMP-2 and calpain 1, the 
exact cleavage sites of titin are unknown and difficult to confirm due to a large size of 
titin (>3 MD). Our data suggest that titin can be cleaved at the N2A domain that 
interacts with SMYD2.  
Overall, our study discussed in this dissertation provides evidence, that SMYD2 
can be selectively glutathionylated at Cys13, and SMYD2 Cys13 glutathionylation 
serves as a key molecular event that leads degradation of sarcomeric proteins in 
response to ROS.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
 All chemicals were purchased from Sigma unless otherwise stated. Amaxa Cell 
Line NucleofectorTM Kit L for H9c2 cell line was purchased from Lonza. All cell culture 
reagents, media and Alexa-Fluor 647 goat anti-mouse IgG (H+L) secondary antibody 
(Cat# A21235) were purchased from Life Technologies. Human Heart QUICK-CLONETM 
cDNA library was purchased from Clontech (Cat# 637213). ProLong Gold Antifade 
Mountant with DAPI, high capacity streptavidin-agarose beads, chemiluminescent 
substrates, HRV 3C Protease Solution Kit (2 units/µL) and Protein G Agarose beads 
were purchased from Thermo Scientific. HRP-conjugated anti-mouse (Cat# NA931), 
anti-rabbit secondary antibodies (Cat# NA934) and Glutathione Sepharose 4 Fast Flow 
beads were purchased from GE healthcare. EDTA-free protease inhibitor cocktail 
tablets were purchased from Roche. Polyethyleneimine-MAX was purchased from 
Polysciences, Inc (USA). Ni-NTA agarose was purchased from QIAGEN. Oxidized 
glutathione and 2, 2-dithiodipyridine were purchased from Acros Organics. S-
Adenosylhomocysteine-D4 was purchased from Cayman chemicals. Human Active 
Matrix Metalloproteinase 2 (MMP-2) was purchased from EMD Milipore and Human 
Calpain 1 was purchased from Sigma. Trypsin Gold, Mass Spectrometry Grade was 
purchased from Promega. SeaKem Gold Agarose (Cat# 50152) was purchased from 
Lonza. SUMO Protease 1 was purchased from LifeSensors. ARP 100 (MMP-2 inhibitor) 
and Acetyl-Calpastatin (184-210) (calpain 1 inhibitor) were purchased from Tocris 
Bioscience. Actin-EGFP 151 (pEGFP-C1 beta actin) and myosin heavy chain-mCherry 
152 (pCMV-mCherry-MHC-IIA) mammalian vectors were obtained from Addgene. 
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2.2 Synthesis of glutathione derivatives 
2.2.1 Synthesis of azido-glutathione using GSM4 enzyme 
 Clickable GSH containing L-azido-Ala (azido-glutathione,N3GSH) was 
synthesized using GS M4 enzyme.  3.5 mM azidoalanine, 3.0 mM  γ-glutamyl-cystein, 
10 mM ATP, 50 mM MgCl2,  300 mM NaCl, 200 mM Tris  buffer (pH = 7.4) and GSM4 
(80 ng) were mixed together in 10 mL final reaction mixture  and incubated overnight 
in 37oC. After acidification of the aqueous solution it was subjected to HPLC 
purification and oxidized form of azido-glutathione (Figure 2.1) was obtained as a 
white solid after lyophilization.  
 Purity and mass were confirmed by ESI-MS and LC/MS. Calculated mass: 722. 
ESI m/z 723 (M+H), 362 (M+2H), 761 (M+ K+) and 381 (M+ K++H). Oxidized azido-
glutathione was reduced using dithiothreitol (DTT) (2 equivalent) in 100 mM PBS (pH 
= 7.4) at room temperature for 2 hrs. Then acidified aqueous sample was subjected to 
HPLC purification and reduced azido-glutathione (Figure 2.2) was obtained as a white 
solid after lyophilization. Purity and mass were confirmed by ESI-MS and LC/MS. 
Calculated mass: 362. ESI m/z 363 (M+H) 725 (2M+H). 
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Figure 2.1. ESI mass spectrum of oxidized azido-glutathione ( N3GSSG N3) 
 
 
Figure 2.2. ESI mass spectrum of azido-glutathione ( N3GSH) 
2.2.2 Synthesis of mixed oxidized form of N3GS-SG, N3GS-8mer, GS-8mer 
 Mixed oxidized glutathione (N3GS-SG, N3GS-8mer, GS-8mer) was synthesized by 
using 2,2’- dithiopyridine. Glutathione (1 equivalent) and 2, 2-dithiodipyridine (2 
equivalant) were mixed in water: methanol (1:1) mixture and stirred for 15-20 hrs at 
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room temperature. After completion of the reaction, methanol was removed by rotary 
evaporation and the aqueous layer was extracted several times with 
dichloromethane153, 154. Then the aqueous portion was subjected to HPLC purification 
and S-(2-thiopyridyl) GSH (Figure 2.3) and N3GSH (Figure 2.4) was obtained as a white  
 
Figure 2.3. ESI mass spectrum of S-(2-thiopyridyl) GSH 
 
 
  
Figure 2.4. ESI mass spectrum of S-(2-thiopyridyl) N3GSH 
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solid after lyophilization. Purity and mass were confirmed by ESI-MS and LC/MS. 
Calculated mass for S-(2-thiopyridyl) GSH : 416. ESI m/z 417 (M+H) 833 (2M+H). 
Calculated mass for S-(2-thiopyridyl) N3GSH: 471. ESI m/z 471 (2M+2H), 943(2M+H). 
 
 
Figure 2.5. ESI mass spectrum of 8mer peptide  (SQLWCLSN) 
 
S-(2-thiopyridyl) N3GSH (1 equivalent) and GSH (1 equivalent) were dissolved in 
100 mM PBS buffer (pH = 7.4) and the reaction mixture was stirred for 2 hrs at room 
temperature for the synthesis of N3GS-SG (Figure 2.6). S-(2-thiopyridyl) N3GSH (1 
equivalent) or S-(2-thiopyridyl) GSH (1 equivalent) was mixed with 8-mer peptide 
(SQLWCLSN) (Figure 2.5) (this peptide was synthesized by using Fmoc solid phase 
peptide synthesis) in 100 mM PBS buffer (pH = 7.4) with 20% acetonitrile and stirred 
for 2 hrs at room temperature for the synthesis of N3GS-8mer (Figure 2.7) and GS-
8mer (Figure 2.8). After completion of the reaction, aqueous layer was extracted with 
dichloromethane for five times to remove the thione by-product.  
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Figure 2.6. ESI mass spectrum of N3GS-SG 
 
 
Figure 2.7. ESI mass spectrum of GS-8mer 
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Figure 2.8. ESI mass spectrum of N3GS-8mer 
 Then aqueous portion was subjected to HPLC  purification and white solids were 
obtained after lyophilization. Calculated mass for N3GS-SG: 667. ESI m/z 668 (M+H) 
334 (M+2H). Calculated mass for N3GS-8mer : 1308. ESI m/z 1309 (M+H) 655 (M+2H). 
Calculated mass for N3GS-8mer: 1254. ESI m/z 628 (M+2H).  
2.3 Spectrophotometric assay of GSTP1 Activity 
 Enzyme assay was carried out in 0.1 M PBS (phosphate buffer saline) (pH 6.5) 
with 1 mM EDTA and1 mM CDNB.  In this assay condition generation of G-SDNB was 
monitored by measuring absorbance at 340 nm using DU730-Beckman coulter UV-VIS 
Spectrophotometer. The rate of spontaneous conjugation of GSH to CDNB was 
subtracted from the rates of GSTP1 catalyzed reactions155. The extinction coefficient 
(9.6 mM-1cm-1) for the G-SDNB at 340 nm was used to calculate the enzyme kinetics156. 
Initial velocity versus substrate concentration plots were fitted to the Michaelis-Menten 
equation using Graphpad prism 5.01 and apparent kinetic constants (Km, Kcat and Vmax) 
for GSH, GSH (L) alkyne and GSH (L) azide were calculated accordingly. 
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Figure 2.9. Gstp1 catalyzes conjugation of GSH and CDNB 
CDNB     = 1-Chloro-2, 4-Dinitrobenzene 
G-SDNB = Glutathione-2, 4-Dinitrobenzene 
2.4 Spectrophotometric assay of Grx1/ GSTO1 Activity 
 
GSH + 8mer-SSG                                                              GSSG + 8mer-SH 
GSSG + NADPH                                                               2GSH + NADP+ 
Figure 2.10. NADPH dependent deglutathionylation by GRX1 and GSTO1. 
 
The coupled spectrophotometric assay was performed in 0.1 M PBS (pH 7.4) 
with 1 mM EDTA, 0.2 mM NADPH, GR (4 units per mL), GSH 0.25 mM and Grx1 (23 
nM) or GSTO1 (0.19 µM) and was incubated for 7 min at 250C157. The reactions were 
initiated by adding the substrate and oxidation of NADPH was monitored at 340 nm 
using DU730-Beckman coulter UV-VIS spectrophotometer158. Non-enzymatic reaction 
was subtracted from the GRX1 (glutaredoxin) catalyzed reaction and extinction 
coefficient (6.2 mM-1cm-1) for the NADPH was used to calculate the enzyme kinetics159. 
Initial velocity versus substrate concentration plots were fitted to the Michaelis-Menten 
equation using Graphpad prism 5.01 and apparent kinetic constants (Km, K cat and Vmax) 
Glutaredoxin 
Glutathione Reductase 
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+ 
for 8mer-SSG, 8mer-SSG (L, D) alkyne and 8mer-SSG (L) azide were calculated 
accordingly. 
2.5 Spectrophotometric assay of GR Activity 
GSSG + NADPH    
Glutathione Reductase        
2 GSH + NADP 
Figure 2.11. NADPH dependent reduction of oxidized GSH by GR. 
 
Kinetic parameters for GR were determined by measuring consumption of 
NADPH in different substrate concentrations (0.01-0.5 mM). NADPH consumption was 
monitored at 25oC by UV absorbance at 340 nm160. The reaction mixture (0.2 mL) 
contains 100 mM PBS (pH 7.4), 1 mM EDTA, 0.2 mM NADPH and 50 ng of GR. The 
extinction coefficient (6.2 mM-1cm-1) for the NADPH   was   used   to   calculate   the   
enzyme   kinetics.   Initial   velocity versus substrate concentration plots were fitted to 
the Michaelis-Menten equation using Graphpad prism 5.01 and apparent kinetic 
constants (Km, Kcat and Vmax) for GSSG, GSSG (L) alkyne and GSSG (L) azide were 
calculated accordingly. 
2.6 Cloning and mutagenesis 
PCR and cloning techniques were applied to construct the pcDNA3.1 (+)-HA-
SMYD2 WT/C13S/C13D/Y24F, pGEX-6p-2 GST-N2A, pET-28a N2A and pcDNA3.1 (+)-
N2A-FLAG. Human titin N2A domain (exon 102-109 or Ig 80-83) (UniProtKB - 
Q8WZ42 (TITIN_HUMAN)) region was amplified by PCR from human cardiac cDNA 
library (Clontech), and cloned into pGEX-6p2 bacterial expression vector: N2A region 
was amplified by using a forward primer (5’-CG CCG CGA ATT CTC ATG GTG GCT 
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GGA AGT GAC ACT ACC AAA TCA AAA GTG ACC-3’) with EcoR1 restriction site, and 
a reverse primer (5’- GCG CGC CTC GAG TCA GGA GTC AGG AAT ATC AGG AGG 
CTT CAG CTC AAG -3’) with Xho1 restriction site, as reported previously 31. PGEX-6p-
2 plasmid and PCR product were double digested with EcoR1 and Xho1. Ligation was 
then performed using T4 DNA ligase. Human GSTP1 cDNA clone (OriGene) and 
Human GSTO1 cDNA clone (gift from Dr. YoungTae Chang, National University of 
Singapore) were subcloned in to pET-28a (+) bacterial expression vector using 
NheI/XhoI (GSTP1) and NdeI/XhoI (GSTO1) restriction sites. PCR reaction was 
performed using forward primer (5'- GCG CGC GCT AGC ATG CCG CCC TAC ACC 
GTG GTC TAT TTC -3') with NheI and reverse primer (5'- GCG CGC CTCGAG TCA 
CTG TTT CCC GTT GCC ATT GAT GGG -3') with XhoI for human GSTP1 cDNA clone. 
Forward primer (5’- GCG CGC CAT ATG ATG TCC GGG GAG TCA GCC AGG-3’) with 
NdeI and reverse primer (5’-GCG CGC CTC GAG TCA GAG CCC ATA GTC ACA GGC 
C-3’) with XhoI were used for the PCR reaction of human GSTO1 cDNA clone. Both 
PCR product and the empty pET-28a (+) vector were double digested with above 
restriction enzymes accordingly and ligated using T4 DNA ligase. For mammalian 
expression vectors, human SMYD2 gene was amplified by PCR with a forward primer 
(5’-GCG CGC GCT AGC ACC ATG AGG GCC GAG GGC CTC -3’) with Kozak 
sequence and Nhe1 restriction site and reverse primer (5’-GCG CGC CTC GAG TCA 
GGC ATA GTC GGG CAC GTC ATA CGG ATA GTG GCT TTC AAT TTC CTG TTT 
GAT CTC AG-3’) with C-terminal HA-tag and Xho1 restriction site. A PCR product of 
SMYD2 gene was sub-cloned into pcDNA3.1/hygro (+) mammalian vector using 
Nhe1/Xho1 sites. For mammalian expression, N2A domain was amplified by PCR with a 
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forward primer containing Kozak sequence, N-terminal FLAG-tag, and BamH1 
restriction site (5’-GCC GCC GGA TCC ACC ATG GAC TAC AAA GAC GAT GAC GAC 
AAG GTG GCT GGA AGT GAC AC-3’) and a reverse primer with Xho1 restriction site 
(5’-CGC CGC CTC GAG TCA GGA GTC AGG AAT ATC AGG AG-3’). All bacterial and 
mammalian mutant vectors of SMYD2 were constructed using quick change 
mutagenesis with following primers: SMYD2 C13S mutation (forward: 5’-GGC CTG 
GAG CGC TTC AGC AGC CCG GGC AAA GGC-3’ and reverse: 5'-GCC TTT GCC 
CGG GCT GCT GAA GCG CTC CAG GCC -3'), C13D mutation (forward: 5’-GGC CTG 
GAG CGC TTC GAC AGC CCG GGC AAA GGC-3’ and reverse: 5’-GCC TTT GCC 
CGG GCT GTC GAA GCG CTC CAG GCC-3’), Y240F mutation (forward: 5’-G GAG 
GTT TTT ACC AGC TTT ATT GAT CTC CTG TAC CC-3’ and reverse: 5’-GG GTA CAG 
GAG ATC AAT AAA GCT GGT AAA AAC CTC C-3’). The entire open reading frame 
(ORF) of all prepared plasmids was confirmed by DNA sequencing and agarose gel 
electrophoresis after digestion with appropriate restriction enzymes.   
2.7 Bacterial expression and purification of proteins 
BL21 (DE3) cells were transformed with pCDF-SUMO-SMYD2 (WT, C13S, or 
C13D). Transformants were grown in LB medium (2 L) at 37oC until OD600 reached 
about 0.5. The protein expression was induced with 0.1 mM IPTG and was incubated 
overnight at 15oC. Cells were harvested by centrifugation at 5,000 rpm for 20 min, and 
lysed by passing French Press three times. Cell lysate was centrifuged at 15,000 rpm 
for 30 min, and the soluble fraction was subjected to Ni2+-NTA affinity column. The 
eluted protein was incubated with SUMO Protease 1 at 4oC for 10 h in a buffer (50 mM 
Tris pH 7.4, 150 mM NaCl and 6 mM β-mercaptoethanol). The mixture was then 
52 
 
incubated with Ni2+-NTA beads to remove His6-SUMO tag and His-SUMO protease. 
Cleaved SMYD2 was collected in the flow-through. SMYD2 protein was finally purified 
by anion exchange column [Mono QTM 5/50 GL cation column (GE Healthcare) with a 
buffer A (50 mM Tris-HCl pH 8.0) and a buffer B (50 mM Tris-HCl, pH 8.0, and 1 M 
NaCl) to homogeneity and concentrated to 4-5 mg/ml. The purified protein was stored in 
a buffer with 50 mM Tris–HCl pH 8.0, 150 mM NaCl, 0.2 mM β-mercaptoethanol and 
5% glycerol. The same approach was applied to express the GST-Hsp90 and GST-N2A 
where proteins were incubated with glutathione beads for purification, and proteins were 
stored in a buffer with 50 mM Tris–HCl pH 8.0, 150 mM NaCl, 0.2 mM β-
mercaptoethanol and 5% glycerol. GST on N2A domain was cleaved using HRV 3C 
Protease Solution Kit (2 units/µL). Initially, GST-N2A was incubated with the HRV 3C 
protease (enzyme/substrate ratio = 1/50) overnight at 4oC in the supplied 1X HRV 3C 
protease reaction buffer. The cleaved mixture was incubated with pre-washed GSH 
beads (three times with 1X HRV 3C protease reaction buffer) for 2 hr at 4oC. The 
cleaved N2A domain was then collected in the flow-through and stored in the same 
buffer (50 mM Tris–HCl pH 8.0, 150 mM NaCl, 0.2 mM β-mercaptoethanol and 5% 
glycerol). GST (S.japonicum) was expressed using pGEX-6P-2 plasmid and purified as 
described elsewhere. All the bacterial expression constructs (pET-HisGSTP1 and pET-
HisGSTO1) were transformed in to BL21 (DE3) cells and transformants were grown at 
37oC until OD600 reached about 0.6 in 1 L LB medium. The protein expression 
(GSTP1 and GSTO1) was induced with 1 mM isopropyl-1-thio-β-D-galactopyranoside 
(IPTG) and was incubated 4-5 hr at 37 oC. The expression of PTP1B was induced 
with 0.2 mM IPTG and was incubated 14 hr at 23 oC The Cells were harvested by 
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centrifugation at 5000 rpm for 20 min and lysed by French Press. Then cell-free lysate 
was centrifuged at 15 000 rpm for 20 min and soluble fraction was purified by Ni2+- 
NTA affinity column. The eluted proteins were dialyzed (50 mM Tris–HCl (pH 8.0), 
150 mM NaCl, 0.1 mM DTT and 5% glycerol) and concentrated. Protein concentrations 
were determined by Bradford assay. 
2.8 Preparation of glutathionylated SMYD2 in vitro 
SMYD2 WT protein was incubated in a buffer (100 mM Tris-HCl pH 7.4 and 150 
mM NaCl) with and without 1 mM oxidized glutathione at 4oC for 4 h, respectively. 
These two samples were then purified by anion exchange column chromatography 
using Mono QTM 5/50 GL cation column (GE healthcare). A linear gradient between a 
buffer A (50 mM Tris-HCl, pH 8.0) and a buffer B (50 mM Tris-HCl, pH 8.0 and 1 M 
NaCl) was used to elute bound proteins while monitoring absorbance at 280 nm. 
Glutathionylation of SMYD2 was confirmed using glutathione antibody (Virogen, Cat# 
101-A-100) (1:1000) by Western blotting. Purified proteins were dialyzed in a buffer (50 
mM Tris–HCl pH 8.0, 150 mM NaCl and 10% glycerol), concentrated, flash-frozen in 
liquid-nitrogen, and stored at -80oC. Protein concentration was determined by Bradford 
assay (BioRad) using bovine serum albumin as the standard. 
2.9 Partial trypsin digestion of SMYD2 
The same amount of purified SMYD2-SH and SMYD2-SSG (5 µg) were mixed 
with trypsin (1 µg) at 37oC. Digestion was quenched in different time points (15, 30, 60 
and 120 min) by an addition of a SDS loading dye and heating at 95oC for 5 min. 
Digested samples were separated on a SDS-PAGE gel, and protein bands were 
visualized by Coomassie stain. 
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2.10 In vitro SMYD2 methyl transferase activity assay 
To evaluate the SMYD2 methyl transferase activity, the level of S-
adenosylhomocysteine (SAH) generated by the enzymatic reaction was quantified 
through the multiple reactions monitoring (MRM) mode in LC-MS/MS with SAH-d4 as an 
internal standard. In MRM mode, the mass transition from the precursor to product was 
used to detect SAH (m/z 385 to 136) and SAH-d4 (m/z 389 to 136) with peak 
quantification 161. The UV absorbance at 260 nm and a molar extinction coefficient of 
15,400 M-1cm-1 162 were used to determine the concentartion of SAM and SAH. The 
calibration curve was made by plotting the integrated peak size versus SAH 
concentrations (10, 50, 100, 250 and 1000 nM). The activity assay was carried out at 
room temperature using 200 nM SMYD2 in a buffer (25 mM Tris-HCl, pH 8.0, and 
0.01% Tween 20). For p53 peptide substrate, SAM (25 μΜ) and p53 peptide (25 μΜ) 
were used. For Hsp90 substrate, SAM (5 μΜ) and Hsp90 (4 μΜ) were used. For N2A 
and GST, SMYD2 was incubated with Hsp90-GST (4 μΜ), N2A (4 μΜ) or GST(4 μΜ), 
followed by additon of SAM (5 μΜ) for 10 min at room temperature. In each experiment, 
methylation reaction was quenched at different time points using 5% TCA.   
2.11 GST pull-down assay 
N-terminal GST-tagged Hsp90 was incubated with glutathione beads at 4oC in a 
buffer (Tris-HCl pH 7.4, 150 mM NaCl) for 1 h. Beads were then washed 3 times with 
the same buffer to remove any unbound protein. Then, an equal amount of SMYD2-SH 
and SMYD2-SSG (purified by ion exchange chromatography) was incubated with 
immobilized Hsp90 on glutathione agarose for 1 h at 4oC. In control, SMYD2 was 
incubated with immobilized GST (S.Japonicum) on glutathione agarose.  Beads were 
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then washed with Tris-HCl (pH 7.4) buffer, and bound proteins were eluted with 1x SDS 
loading dye, and separated on the SDS-PAGE gel. GST-N2A or GST-Hsp90 interaction 
with SMYD2 or SMYD2 C13D was analyzed in the same manner 
2.12 In vitro glutathionylation of SMYD2 with azido-glutathione 
Glutathionylation of purified SMYD2 WT (10 µg) and C13S (10 µg) was induced 
in 50 mM PBS buffer containing 1 mM azido-glutathione by adding different 
concentrations of H2O2 or diamide (0, 1, 10, 50 and 100 μM) for 5 min at room 
temperature. Glutathionylation was quenched by addition of iodoacetamide (20 mM) for 
15 min at 37oC in the presence of 1% SDS. Proteins were pelleted by adding cold 
acetone (-20oC for 30 min). Proteins were re-suspended in 50 mM PBS with 1% SDS, 
and were subjected to click reaction using 0.2 mM rhodamine-alkyne, 0.8 mM Tris (3-
hydroxypropyltriazolylmethyl) amine (THPTA), 1 mM CuBr for 1 h at 37oC. A dose-
dependent signal of protein glutathionylation was monitored in a protein gel by 
fluorescence. To monitor the extent of glutathionylation in SMYD2 WT compared to 
C13S, the similar approach was used by adding 1 mM oxidized azido-glutathione 
(N3GSSGN3) for the induction. Proteins were then precipitated by cold acetone 
treatment, and washed with cold methanol to remove unreacted rhodamine. Proteins 
were then dissolved in a PBS buffer, and absorbance was taken at 550 nm and used to 
calculate the bound concentration of rhodamine with a molar extinction coefficient 
(65,000 M-1cm-1) (a sample without oxidized azido-glutathione was used as a control). 
SMYD2 concentration was quantified in gel analysis by using ImageJ program in 
comparison to a standard curve made of BSA. A ratio of SMYD2 to rhodamine 
concentration was plotted versus time to analyze the level of modification.  
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 An In vitro mass-tag approach was performed with SMYD2 WT and C13S in a 
similar condition using 2-kD PEG-alkyne (0.4 mM). The gel-shift of SMYD2 was 
analyzed by SDS-PAGE gel electrophoresis. The synthesis of reduced and oxidized 
forms of azido glutathione is described previously.  
2.13 Mass identification of the cysteine site of glutathionylation in SMYD2 
To a PBS solution (45 µL) containing SMYD2 (100 µg) and azido-glutathione 
(1.25 mM) was added diamide (100 µM). The solution was allowed to sit at room 
temperature for 1 hour after which SDS (final 1%) and iodoacetamide (final 20 mM) 
were added. The solution was incubated at 370C for 20 minutes and then cold acetone 
(4 volumes) was added. The solution was kept at -20oC for 20 minutes, followed by 
centrifugation at 7,000 RPM for 5 minutes. The acetone was removed and the protein 
pellet was suspended in 1% SDS in PBS (36 µL). The samples were briefly sonicated 
until all of the proteins had been dissolved, and subjected to click reaction by adding 
biotin-DDE-alkyne (4 µL of a 5 mM stock solution in DMSO), and a premixed solution of 
THPTA (5 µL of a 20 mM solution in water, final 2 mM) and Cu(I)Br (5 µL of a 20 mM 
solution in 3:1 DMSO and tert-butanol, final 2 mM). This reaction was allowed to sit at 
37oC for 1 hour, after which EDTA was added (1 µL of 100 mM solution) and kept at 
room temperature for 15 minutes. The proteins were precipitated by adding cold 
acetone (4 volumes) for 20 minutes at -20oC. The solutions were centrifuged at 7,000 
RPM for 5 minutes and the supernatant removed. Cold methanol was added to the 
pellet and briefly sonicated. The resulting suspension was kept at –20oC for 20 minutes. 
The protein was pelleted by centrifugation at 7,000 RPM for 5 minutes, and the 
supernatant was removed. To the pellet was added a 50 µL of denaturation buffer (8 M 
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urea, 4 mM CaCl2 in 1x PBS). The solution was briefly sonicated and kept at 37
oC for 1 
hour. The solution was diluted with 150 µL of 1x PBS to make the final concentrations of 
urea (2 M) and CaCl2 (1 mM), and allowed to digest by trypsin (3 µg) overnight at 37
oC. 
The solution containing the digested peptides was added to streptavidin-agarose resin 
(50 µL bead volume) in PBS (5 mL). The mixture was incubated with rotation at room 
temperature for 2 hr. The beads were pelleted by centrifuging at 2,000 RPM for 2 
minutes and washed with 0.2% SDS in PBS (5 mL) followed by PBS (3 X 5 mL). The 
bound peptides were then eluted with a 2% hydrazine solution in PBS (3 X 30 µL, pH 
7.4, 30 minutes-incubation for the first two volumes and a wash for the last). The eluted 
fractions were combined and then acidified with a 5% formic acid solution. The sample 
was subjected to zip-tip purification and used for MALDI-TOF/TOF analysis with α-
cyano-hydroxycinnamic acid (CHCA) as the matrix.   
2.14 Cell culture, differentiation and induction of glutathionylation   
Neonatal Rat Ventricular Cardiomyocytes (P1-2) (Lonza, R-CM-561) were 
cultured on nitrocellulose coated plates by following the company protocol and using the 
media (Lonza, CC-4515) provided by the company. HL-1 cells (kindly provided by Dr. 
Karin Przyklenk, WSU) were cultured in Claycomb medium (Sigma, 51800C) 
supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 0.1 mM 
norepinephrine and 2 mM L-glutamine in fibronectin–gelatin-coated flasks. A H9c2 cell 
line was obtained from America Tissue Type Collection (ATTC, CRL-1446), and 
cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 100 units/ml penicillin and 100 μg/ml streptomycin. All the cell lines 
were cultured at 37oC in a 5% CO2 humidified atmosphere. 
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 H9c2 cells were sub-cultured when reaching a 70–80% confluence to maintain 
the differentiation potential of H9c2 cells. H9c2 myoblasts were differentiated by 
switching to DMEM medium containing 1% FBS with supplementation of trans-retinoic 
acid (1 μM). A differentiation medium (1% FBS, 1% penicillin/streptomycin, and 1 μM 
all-trans-retinoic acid) were maintained over 5 days. After differentiation, cells were 
subjected to DMEM medium containing 2% FBS, and infected with adenovirus-
expressing GS M4 (Ad/GS M4) (prepared from Vector Biolabs). Briefly, adenovirus 
(MOI = 25) was incubated with polybrene (10 µg/mL) in DMEM medium containing 2% 
FBS for 15 min, and added to differentiated H9c2 cells. The medium containing 
adenovirus was removed after 6 h. Cells were then incubated for 18 h in 10% FBS 
complete medium and further incubated with L-azido-Ala (0.6 mM) for 20 h. Cells were 
then washed and serum starved for 4 h before inducing for glutathionylation with 
different stimuli, including H2O2 and antimycin A respectively. After inducing 
glutathionylation, cells were lysed with a lysis buffer [100 mM Tris-HCl, 150 mM NaCl, 
pH 7.4, 0.1% Tween 20, a protease inhibitor cocktail tablet, 100 µM PMSF and 50 mM 
N-ethylmaleimide (NEM)]. Collected lysates were incubated at 4oC for 30 min. After 
centrifugation at 16,000 rpm for 15 min, the supernatant was collected and protein 
concentration was measured by Bradford assay.  
A HEK293 cell line stably expressing GS M4 (HEK 293/GSM4) 128 was 
maintained in DMEM medium with 10% FBS, 100 units/mL penicillin, 100 μg/mL 
streptomycin and 100 µg/mL hygromycin B at 37°C in a 5% CO2 humidified 
atmosphere. For induction of glutathionylation, HEK293-GSM4 cells were transfected 
with HA-tagged SMYD2 WT or C13S mutant using PEI-MAX as the transfecting agent. 
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After 24 h, cells were incubated with azido-Ala (0.6 mM) and induced for 
glutathionylation by adding antimycin A (2 µg/mL) in glucose-free media for 2 h. Cells 
were then lysed in a lysis buffer (100 mM Tris-HCl, 150 mM NaCl, pH 7.4, 0.1% Tween 
20, a protease inhibitor cocktail tablet, 100 µM PMSF and 50 mM N-ethylmaleimide). 
Lysates were collected in the same manner to H9c2 cells. 
2.15 Click reaction and pull down of glutathionylated proteins  
Cell lysates collected after inducing glutathionylation from HEK293-GSM4 or 
H9c2 expressing GS M4 were incubated with 4X volume of cold acetone for 30 min at -
20oC. The precipitated proteins were then centrifuged, and protein pellet was re-
dissolved in PBS with a brief sonication. The re-suspended proteins were subjected to 
click reaction with 0.2 mM biotin-alkyne, rhodamine-alkyne, or Cy5-alkyne, 1 mM CuBr 
and 0.4 mM Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA). A click reaction 
mixture was incubated at room temperature for 1 h, and run on SDS-PAGE for 
fluorescence detection when using rhodamine-alkyne or Cy5-alkyne. For pull down of 
glutathionylated proteins, a click reaction mixture with biotin-alkyne was treated again 
with 4X volume of cold acetone, and incubated for 30 minutes at -20oC. Protein pellet 
was then completely dissolved in TBS buffer (100 mM Tris-HCl and 150 mM NaCl) 
containing 10% SDS with sonication for 20 seconds. The re-dissolved proteins were 
diluted with TBS (100 times dilution) and incubated with pre-washed streptavidin 
agarose beads for 3 h at room temperature. After washing beads with TBST (5 mL) 
three times, beads were then eluted with a SDS loading buffer, and eluted proteins were 
separated from running on SDS-PAGE gel for detection of glutathionylated proteins 
(SMYD2, or Hsp90) by Western blotting. For SMYD2, blots were probed with mouse 
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anti-HA antibody (Biolegend, Cat# 901502) or rabbit SMYD2 antibody (Cell Signaling 
Technology, Cat# 9734). For HSP90, blots were probed with mouse anti-HSP90 (BD 
transduction, Cat# 610418).  
 For mass-shift analysis of SMYD2, H9c2 cells, after expressing of GS M4 and 
incubation of azido-Ala, were treated with antimycin A (2 μg/mL) for 1 h or 12 h. Lysates 
were subjected to click reaction with 2-kD PEG-alkyne twice to assure the complete 
conjugation (after first click reaction for 2 h at 37oC, lysates were precipitated by 
acetone and re-dissolved in a TBST buffer, and re-subjected to the second click 
reaction for 4 h at 37oC). Cell lysates were then separated on SDS-PAGE gel and were 
analyzed by Western blotting. The blot was probed with rabbit SMYD2 antibody (Cell 
Signaling Technology, Cat# 9734) to see a mass shift of SMYD2. 
2.16 siRNA mediated knockdown of SMYD2 and MMP-2 
H9c2 cells were transfected two times during the differentiation process by using 
Lipofectamine 3000 with SMYD2 siRNA (100 nM) (Santa Cruz Biotechnology, sc-
76530) or MMP-2 siRNA (100 nM) (Santa Cruz Biotechnology, sc-37264). As a 
negative, control siRNA (Santa Cruz Biotechnology, sc-37007) was used. 
2.17 Cell viability assay 
SMYD2 WT and C13S were expressed in H9c2 myoblasts by electroporation 
using NucleofectorTM 2b device (Lonza), according to manufacturer protocols. After 
electroporation, cells were seeded onto six-well plates at a density of 2.5 x 105 cells/well 
with 10% FBS supplemented DMEM medium (3 mL) for 2 days, and then switched to a 
differentiation medium (1% FBS, 1% penicillin/streptomycin, and 1 μM all-trans-retinoic 
acid). Differentiated H9c2 myocytes were treated with H2O2 (25 μM), antimycin A (2 
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μg/mL), nitric oxide donor (NONOate, 100 μM), angiotensin II (1 μM), or DMSO 
(vehicle) in a serum-free DMEM medium for 24 hrs. Cell viability was then measured by 
Trypan blue assay. Briefly, after removal of the medium, cells were washed once with 
PBS, and treated with trypsin to detach cells from plates. Cells were then re-suspended 
in culture medium, and mixed with 0.4% trypan blue sterile-filtered solution (1 part of 
trypan blue and 1 part of cell suspension) by gently pipetting up and down for 10 times. 
10 µL of the mixture was then loaded into the opening of either chamber on the counting 
slide (BioRad) and cell number was determined by TC20 automated cell counter 
(BioRad).  
 In the same procedure, cell viability was measured for differentiated H9c2 
myocytes transfected with empty pcDNA3.1 and pcDNA3.1-HA-SMYD2 WT by 
electroporation, after inducing glutathionylation by treatment of antimycin A. Similarly, 
differentiated H9c2 cells were transfected with SMYD2 siRNA, MMP-2 siRNA and 
control siRNA by using Lipofectamine 3000. Cell viability was measured after incubation 
of antimycin A (2 μg/mL) for 24 h.  
 The same approach was used to measure the viability of H9c2 myocyte in the 
presence of MMP-2 inhibitor (ARP 100) or calpain inhibitor (acetyl-calpastatin). Briefly, 
cells were pre-incubated with acetyl-calpastatin (5 µM) or ARP 100 (1 µM) for 1 h at 
37oC in serum free media before incubation of antimycin A (2 μg/mL) for 24 h. Trypan 
blue assay was then carried out to analyze the percentage of viable cells compared to 
total cells. 
2.18 Immunofluorescence and immunostaining 
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Neonatal Rat Ventricular Cardiomyocytes were transfected with SMYD2 or C13S 
mRNA using Lipofectamine MessengerMAX Transfection Reagent (invitrogen), and 
mRNA were synthesized using mMESSAGE mMACHINE T7 ULTRA Transcription Kit 
(Invitrogen). For titin and SMYD2, and α-actinin immunostaining, neonatal rat ventricular 
cardiomyocytes and differentiated H9c2 cells expressing SMYD2 WT or C13S were 
incubated with antimycin A (2 µg/mL) for 12 h. Cells were then washed 3 times with 
cold-PBS and fixed with either 4% paraformaldehyde for 10-20 min at room temperature 
or ice-cold methanol for 10-15 min at -20oC. After fixation, cells were washed with PBS 
for 3x times and paraformaldehyde fixed cells were incubated 10-15 min at room 
temperature in a permeabilization buffer (1x PBS with 0.1% Triton X-100). Cells were 
then kept on a blocking buffer (1x PBS with 0.1% TWEEN-20 and 3% BSA) for 1 h at 
room temperature. Subsequently, cells were incubated with primary antibodies in a 
blocking buffer overnight at 4oC. The following antibodies were used: Titin rabbit 
antibody (Novus biologicals, Cat# NBP 1-88071, I band region of titin) (1:100 dilution), 
SMYD2 mouse antibody (Sigma, Cat# SAB1407760) (1:100 dilution), SMYD2 rabbit 
antibody (Cell Signaling Technology, Cat# 9734) (1:100 dilution), HA-tag (6E2) mouse 
antibody (conjugated with Alexa Fluor 488) (Cell Signaling Technology, Cat# 2350S) 
and α-actinin mouse antibody (Abcam, Cat# ab9465) (1:100 dilution). After washing 
several times with PBS, cells were incubated for 1 h at room temperature with the 
following Alexa Fluor conjugated secondary antibodies: anti-rabbit Alexa Fluor 647 
secondary antibody (Invitrogen, Cat# A-21244), anti-mouse Alexa Fluor 647 secondary 
antibody (Invitrogen, Cat# A-21235), anti-rabbit Alexa Fluor 488 secondary antibody 
(Invitrogen, Cat# A-11008) and anti-mouse Alexa Fluor 488 secondary antibody 
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(Invitrogen, Cat# A-11001). Cells were then washed extensively with 1x PBS, and cover 
slips were mounted onto the microscopic plate with a DAPI-containing mounting 
solution. Cells were then analyzed under confocal microscope.  
PcDNA3.1-HA-SMYD2 WT or pcDNA3.1-HA-SMYD2 C13S was co-transfected 
with either pEGFP-C1 beta-actin or pCMV-mCherry-MHC-IIA by electroporation using 
NucleofectorTM 2b device (Lonza). After electroporation, cells were seeded onto six-well 
plates at a density of 2.5 x 105 cells/well with 10% FBS supplemented DMEM medium 
(3 mL) for 2 days, and then switched to a differentiation medium (1% FBS, 1% 
penicillin/streptomycin, and 1 μM all-trans-retinoic acid) for 4 days. Differentiated H9c2 
myocytes were then kept on serum-free-medium for 12 hrs. Subsequently, cells were 
treated with antimycin A (2 μg/mL) for 12 hrs. Cells were then washed 3 times with cold-
PBS and fixed with 4% paraformaldehyde for 10 min at room temperature. After 
washing thoroughly with PBS, cells were incubated on a blocking buffer (1xPBS with 
0.1% TWEEN-20 and 3% BSA) for 1 h at room temperature. After washing with PBS, 
cover slips were mounted onto the microscopic plate after adding a DAPI-containing 
mounting solution. Cells were then analyzed under confocal microscope.  
 In all experiments with titin, SMYD2, α-actinin, actin-EGFP, myosin-mCherry, 
about 30 cells were photographed and observed for a staining pattern of myofibrils: 
photographed pictures were analyzed by using Fiji-imageJ software with orientation J 
distribution plugin to count the number of cells that retain aligned myofibrils or 
misaligned myofibrils [the aligned myofibrils were determined by following definition: 
Orientation degrees between (+20) and (-20) and Distribution of orientation > 10,000] 
Volocity 6.3.1 software was utilized to obtain the Pearson’s Correlation Coefficient (Rr) 
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for the colocalization between titin and SMYD2 [the co-localization status was estimated 
by the Pearson’s coefficient values with the following definition: weak correlation = (-
0.26)-0.09, moderate correlation = 0.1-0.48, and strong correlation = 0.49-0.84]. All 
fluorescence images were captured by Zeiss LSM 780 Confocal Microscope using 
(100X/1.4NA, 63X/1.4NA and 40X/1.3NA) oil objectives. The following laser was used 
for individual channels: Diode laser (405 nm) for excitation of DAPI (emission: 410-467 
nm); Argon laser (488 nm) for excitation of EGFP (emission: 499-552 nm); Diode 
Pumped Solid State (DPSS) laser (561 nm) for excitation of mCherry (emission: 572-
647 nm); HeNe laser (633 nm) for excitation of Alexa 647 (emission: 640-721 nm). 
2.19 Immunoblotting analysis  
Differentiated H9c2 myocytes or HL-1 cardiomyocytes expressing in SMYD2-HA 
WT or C13S was serum starved for 12 h, and treated with antimycin A (2 μg/mL). Cells 
were then washed with cold PBS and lysed with a lysis buffer and protein 
concentrations were measured by Bradford assay. Cell lysates from each sample were 
separated on a protein gel and transferred into PVDF membrane. Then membrane was 
blocked and incubated with primary antibodies, including α-actinin (Abcam, Cat# 
ab9465) (1:500), Hsp90 (BD transduction, Cat# 610418) (1:1000), actin (Abcam, Cat# 
ab3280) (1:2000), HA-tag (Biolegend, Cat# 901502) (1:1000), cardiac heavy chain 
myosin (Abcam, ab50967) (1:200), troponin I (Cell Signaling Technology, Cat#4002S) 
(1:1000), and β-tubulin (Santa Cruz) (1:1000) diluted in a blocking buffer at 4oC 
overnight. Protein levels were then visualized by chemiluminescence using appropriate 
HRP-conjugated secondary antibodies.  
65 
 
 In a similar experiment, H9c2 myocytes were treated with antimycin A after 
knockdown of SMYD2 or MMP-2 using siRNA. Western blot was performed and 
analyzed for α-actinin, troponin I, SMYD2 and MMP-2 using following primary 
antibodies: SMYD2 (Cell Signaling Technology, Cat# 9734) (1:1000), and MMP-2 (Cell 
Signaling Technology, Cat#4022S) (1:1000). Similarly, a MMP-2 inhibitor (ARP 100, 10 
µM) was incubated with H9c2 myocytes transfected with SMYD2 WT at 37oC for 1 h 
before treatment of antimycin A, and the α-actinin level was compared in the presence 
versus absence of antimycin A (2 μg/mL) by Western blotting.  
2.20 Co-immunoprecipitation analysis 
For co-immunoprecipitation of Hsp90 and SMYD2, HEK293 cells were 
transfected with plasmids containing SMYD2-HA WT or C13S, using PEI-MAX. After 2 
days, cells were incubated with serum-free DMEM for 4 h, and further incubated in 
glucose-free DMEM (glucose deprivation) with treatment of antimycin A (2 μg/mL) for 2 
h. Cells were then lysed at 4oC for 30 min in a lysis buffer (100 mM Tris-HCl pH 7.4, 
NaCl 150 mM, 0.1% Tween 20 and protease inhibitor cocktail). Cell lysate (1 mg) were 
mixed with HSP90 antibody (BD Bioscience, Cat# 610418) for 1 h at 4oC. This mixture 
was then incubated with Protein-G agarose beads (pre-washed with a 1xTBST buffer) 
for overnight at 4oC. Beads were washed with 3 times with a 1xTBST buffer, and bound 
proteins were eluted using a SDS loading buffer. Eluted proteins were separated on a 
SDS-PAGE gel and transferred into PVDF membrane. Membrane was blocked by a 
blocking buffer (1xTBS with 0.1% TWEEN-20 and 3% BSA) for 1 h at room temperature 
and incubated with mouse Hsp90 antibody (BD transduction, Cat# 610418) or HA-
antibody (Biolegend, Cat# 901502) diluted in a blocking buffer at 4oC for overnight. After 
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washing 5 times with a TBST buffer, membrane was incubated with HRP-conjugated 
mouse secondary antibody (GE health care, Cat # NA931) for 1 h at RT. Membrane 
was then washed 3 times with a TBST buffer and visualized by chemi-luminescence. 
For N2A-FLAG and SMYD2-HA co-immunoprecipitation, the same approach was used 
after transfection of a plasmid-containing N2A-FLAG (pcDNA N2A-FLAG). HA-antibody 
(Biolegend, Cat# 901502) was used for immunoprecipitation in the same manner. For 
co-immunoprecipitation of SMYD2-HA C13D with Hsp90 or N2A, HA-antibody 
(Biolegend, Cat# 901502) was used for immunoprecipitation in the same manner.  
2.21 Detection of Hsp90 methylation and SMYD2 oxidation (sulfonic acid) 
For detection of Hsp90 methylation, differentiated H9C2 myocytes, without or 
with SMYD2 knockdown, were treated with antimycin A (2 μg/mL). After lysis, Hsp90 
was immunoprecipitated, using mouse Hsp90 antibody (BD transduction, Cat# 610418) 
and then probed with rabbit mono-methyl lysine (me-K) (Cell Signaling Technology, 
Cat#14679) (1:1000) to analyze the methylation level of HSP90. The rabbit mono-
methyl lysine (me-K) antibody was validated, after performing in vitro SMYD2 methyl 
transferase assay with purified Hsp90; Briefly, SMYD2 (200 nM) was incubated with 
Hsp90 (2 µg) and SAM (25 uM). At different time points, the enzyme activity was 
quenched by addition of an SDS-loading dye. The samples were separated on a SDS 
gel, transferred to membrane, and probed with antibodies to Hsp90 and me-K for 
Western blotting.  
 For detection of sulfonic acid in SMYD2, differentiated H9c2 myocytes 
expressing SMYD2-HA WT or C13S was serum starved for 12 h, and treated with 
antimycin A (2 μg/mL) for 12 h. Cells were then lysed with a lysis buffer containing 
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iodoacetamide (25 mM). Immunoprecipitation was performed with mouse HA-antibody 
(Biolegend, Cat# 901502) and blot was probed with rabbit cysteine (sulfonate) antibody 
(Enzo Life Sciences, Cat# ADI-OSA-820-D), which can detect sulfinic acid or sulfonic 
acid. The rabbit cysteine (sulfonate) antibody was validated with purified SMYD2 using 
an in vitro assay; briefly, SMYD2 was incubated with H2O2 (10 mM) for 20 min at room 
temperature or after pretreatment of iodoacetamide (25 mM) to block cysteine oxidation 
as a negative control. Samples were run on a gel for Western blotting with SMYD2 
antibody or cysteine (sulfonate) antibody. 
2.22 Dot-blot analysis of titin 
Differentiated H9c2 myocytes or HL-1 cardiomyocytes expressing in SMYD2-HA 
WT or C13S (by SMYD2 or C13S mRNA transfection) was serum starved for 12 h, and 
treated with antimycin A (2 μg/mL). Titin was immunoprecipitated, following a previously 
reported method 163, 164. First, plates were washed 2 times with a PBS buffer containing 
MgCI2 (2 mM) and EGTA (1 mM) and incubated with an extraction buffer (100 mM KCI, 
10 mM Pipes, pH 6.8, 300 mM sucrose, 2 mM MgCl2, 1 mM EGTA, 0.1 mM PMSF, 10 
μM E-64, 100 μM leupeptin, protease inhibitor cleavage cocktail and DNase1) 
containing 0.5% Triton X-100 for 10 min on ice. After collecting the initial extractable 
fraction, Triton-resistant material was scraped into the cytoskeletal-fraction-removal 
buffer (the extraction buffer with 2% SDS, 75 mM β-mercaptoethanol and 100 mM 
NaCI, instead of KCI). Then, scraped portion was heated at 60oC for 10 min, and 
passed through a 1 mL syringe with a needle for 5-10 times to homogenize the solution. 
Lysates were diluted with a non-denaturing lysis buffer (20 mM Tris HCl pH 8, 140 mM 
NaCl, 1% Triton X-100, protease inhibitors and 2 mM EDTA), and dialyzed against the 
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same non-denaturing lysis buffer containing 0.05% SDS and protease inhibitors. Cell 
lysates (5 mg) were mixed with titin (E-2) mouse antibody (α-titin-CT) (Santa Cruz, 
sc271946) for 4 h at 4oC. This mixture was then incubated with Protein-G agarose 
beads (pre-washed 2 times with a non-denaturing buffer) for overnight at 4oC. Beads 
were washed 3 times with a non-denaturing buffer, and bound proteins were eluted 
using a 0.05 % SDS in buffer by boiling the beads at 90oC for 10 min. Eluted proteins 
were then diluted and blotted onto a PVDF membrane, using Bio-Rad Bio-Dot Blot 
micro-filtration Apparatus with 96 wells. Membrane was blocked by a blocking buffer 
(1xTBS with 0.1% TWEEN-20 and 3% BSA) for 1 h at room temperature, and probed 
with following primary antibodies: titin rabbit antibody (Novus biologicals, Cat# NBP 1-
88071)(1:1000) (titin-NT), titin mouse antibody (Santa Cruz, sc271946) (α-titin-CT) 
(1:1000), HA-antibody (Biolegend, Cat# 901502)(1:1000), and β-tubulin (Santa Cruz) 
(1:1000) to observe the cleavage or degradation of titin.  
2.23 In vitro degradation of N2A by matrix metalloproteinase 2 (MMP-2) 
Purified N2A (3 µg) was incubated with human recombinant active MMP2 in a 
buffer (Tris-HCl pH 7.4, 150 mM NaCl and 5 mM CaCl2) at 37
oC with an increasing 
incubation time (1-5 h) or an increasing amount of MMP-2 (0.05, 0.1, 0.15 µg) for 2 h. 
Each reaction was quenched with a SDS loading dye at 95oC for 5 min. Proteins were 
then separated by 10% SDS-PAGE gel, and visualized by Coomassie blue stain. In the 
similar manner, N2A was incubated with MMP-2 at 370C for 4 h with an increasing 
amount of SMYD2 (C13S) (a ratio of N2A to SMYD2 was 1:1.5, 1:3 and 1:5), and 
proteins were resolved on 10% SDS-PAGE gel and analyzed by Coomassie blue stain 
165 
69 
 
2.24 In vitro degradation of N2A by calpain 1 
Purified N2A (3 µg) was incubated with human recombinant calpain 1 in a buffer 
(Tris-HCl pH 7.4, 150 mM NaCl, 1 mM CaCl2 and 1 mM beta mercaptoethanol) at room 
temperature with an increasing incubation time (15-60 min) or an increasing amount of 
calpain 1 (0.05, 0.5, 1.0 µg) for 1 h. Each reaction was quenched with a SDS loading 
dye at 95oC for 5 min. Proteins were then separated by 10% SDS-PAGE gel, and 
visualized by Coomassie blue stain. In the similar manner, N2A was incubated with 
calpain 1 at room temperature for 2 h with an increasing amount of SMYD2 (C13S) (a 
ratio of N2A to SMYD2 was 1:0.6, 1:1.5 and 1:3), and proteins were resolved on 10% 
SDS-PAGE gel and analyzed by Coomassie blue stain.  
2.25 Isolation and digestion of myofibrils  
C57BL/6 mice were used under the guidelines of protocols approved by the 
Wayne State University Animal Care and Use Committee. Gastrocnemius muscle of 2-
3-month-old mice were rapidly removed after euthanasia and rinsed with ice-cold PBS. 
The tissue was flash-frozen and stored in liquid nitrogen until use. Skeletal myofibrils 
were isolated from mouse gastrocnemius muscle according to the method described 
previously 166. Initially the frozen muscle was thawed on ice and cut into small pieces, 
followed by homogenization in a cold lysis buffer [10 mM Tris-HCl, pH 7.0, 5 mM EGTA, 
130 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM NaN3, 1 mM DTT, 0.1 mM PMSF, 10 μM 
E-64, 100 μM leupeptin and protease inhibitor cleavage cocktail (Thermo Scientific, 
Cat# A32955)] using an electronic homogenizer. Homogenates were then pelleted at 
4oC by centrifuging for 5 min at 2500g. Pellets were then washed in a cold washing 
buffer [60 mM KCl, 30 mM imidazole (pH 7.0), 2 mM MgCl2, 1 mM DTT, 0.1 mM PMSF, 
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10 μM E-64, 100 μM leupeptin and protease inhibitor cleavage cocktail] with 0.5% (v/v) 
Triton X-100 for once and without Triton X-100 for three times. 
 Myofibrils were then suspended in a cold suspension buffer (20 mM MOPS, pH 
7.0, 1 mM EGTA, 5 mM MgCl2, 100 mM KCl, 0.1 mM PMSF, 10 μM E-64, 100 μM 
leupeptin and protease inhibitor cleavage cocktail), and filtered through a 70 µm pore 
size nylon mesh (sterile cell strainer) (Fisher Scientific, Cat# 22363548), and stored in 
4oC until its use. Myofibril digestion was performed according to the previous method 
167. Briefly, freshly prepared myofibrils were washed 3 times using a suspension buffer 
without protease inhibitors, and incubated with human recombinant active MMP-2 (0.4 
µg) in a buffer (Tris-HCl pH 7.4, 150 mM NaCl, 2.0 mM CaCl2) at 37
oC with an 
increasing incubation time (0-30 min). In the same experiment, MMP-2 was pre-
incubated with ARP100 (100 nM) for 15 min at 37°C before adding to the myofibril 
digestion mixture. Alternatively, myofibrils were pre-incubated with excess amount of 
SMYD2 (25 µg) for 15 min at 37°C, and then subjected to MMP-2 digestion.  
2.26 Electrophoresis of titin 
The mixture was then denatured using a 2X urea loading buffer (8M urea, 2M 
thiourea, 3% SDS, 75 mM dithiothreitol, 0.03% bromophenol blue, 25% glycerol and 
0.05 M Tris-HCl; pH 6.8). Before loading to the gel, all the samples were mixed with 
60% glycerol solution (making glycerol as 25% in the final volume). The proteins were 
then separated by 1% vertical sodium dodecyl sulfate (SDS)-agarose gel, using a lower 
buffer (50 mM Tris-base, 0.384 M glycine, and 0.1% SDS) and the same buffer with 10 
mM 2-mercaptoethanol as the upper buffer in the Hoefer™ SE 600 Chroma Vertical 
Electrophoresis System, according to a method described previously 168. 
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2.27 Statistical analysis  
Data are represented as the means ± SD and were statistically analyzed by 
Student’s t test with Welch’s correction. The value p<0.05 was considered as 
statistically significant. 
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CHAPTER 3: RESULTS 
Portions of the text in this chapter were reprinted or adapted with permission from: 
Samarasinghe, K.T. et al. A clickable glutathione approach for identification of protein 
glutathionylation in response to glucose metabolism. Mol Biosyst 12, 2471-2480 (2016) 
Copyright 2016, Royal Society of Chemistry 
3.1 Clickable glutathione is catalyzed by enzymes implicated in glutathionylation 
In order to analyze the reversible change of protein glutathionylation, we begin to 
determine whether clickable glutathione can detect the reversible change of 
glutathionylation99.  
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Figure 3.1. Enzyme kinetic data of clickable GSH substrate catalyzed by Gstp1. (a) 
Endogenous glutathione (b) Clickable derivative of glutathione (c and d) Initial velocity 
versus substrate concentration plots were fitted to the Michaelis-Menten equation using 
Graphpad prism 5.01. (e) Apparent kinetic constants (Km, Kcat and Vmax) for GSH and  
N3GSH 
 
Glutathionylation can occur by non-enzymatic reactions of protein cysteine 
residues with glutathione in the presence of ROS. However, redox enzymes may 
facilitate formation of glutathionylation. Glutathione-S-transferase pi (GSTP) was shown 
to catalyze formation of glutathionylation100.  
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Figure 3.2. Enzyme kinetic data of clickable GSH substrate catalyzed by GR. (a) 
Endogenous oxidized glutathione (b) Clickable derivative of oxidized glutathione (c and 
d) Initial velocity versus substrate concentration plots were fitted to the Michaelis-
Menten equation using Graphpad prism 5.01. (e) Apparent kinetic constants (Km, Kcat 
and Vmax) for GS-SG and 
N3GS-SG 
 
Deglutathionylation (reduction of glutathionylation) can occur by non-enzymatic 
reactions. However, glutaredoxin 1 (Grx1)169, together with glutathione reductase (GR), 
catalyzes deglutathionylation with about 1,000- fold higher rate than glutathione alone. 
Also, glutathione-S-transferase omega (GSTO) was recently shown to catalyze 
deglutathionylation101.  
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Figure 3.3. Enzyme kinetic data of clickable GSH substrate catalyzed by Grx1. (a) 
Glutathionylated peptide (b) Glutathionylated peptide with clickable handle (c and d) 
Initial velocity versus substrate concentration plots were fitted to the Michaelis-Menten 
equation using Graphpad prism 5.01. (e) Apparent kinetic constants (Km, Kcat and Vmax) 
for GS-8mer and N3GS-8mer. 
 
A few other redox enzymes, such as thioredoxin170 and sulfiredoxin171, may 
contribute to deglutathionylation although their specificity for deglutathionylation is low. 
Despite the small size of azido-group in glutathione, it may interfere with enzyme-
mediated (de)glutathionylation.  
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Figure 3.4. Enzyme kinetic data of clickable GSH substrate catalyzed by GSTO1. 
(a) Glutathionylated peptide (b) Glutathionylated peptide with clickable handle (c and d) 
Initial velocity versus substrate concentration plots were fitted to the Michaelis-Menten 
equation using Graphpad prism 5.01. (e) Apparent kinetic constants (Km, Kcat and Vmax) 
for GS-8mer and N3GS-8mer. 
 
In order to determine whether azido-glutathione can be used as a substrate of 
major enzymes involved in glutathionylation, we have prepared substrates of Grx1 
(Figure 3.3a and b), GSTO1 (Figure 3.4a and b), GR (Figure 3.2a and b) and GSTP1 
(Figure 3.1a and b) that contain either endogenous glutathione (GSH) or azido 
glutathione (N3GSH) for kinetic comparisons. The model peptides (SQLWCLSN) 
glutathionylated by GSH or N3GSH were prepared and assayed for deglutathionylation 
by Grx1 and GSTO172. Disulfides of GSH (GSSG and N3GSSG) were used for 
substrate of GR. In the kinetic data, it is notable that Grx1 (Figure 3.3c, d and e), 
GSTO1 (Figure 3.4c, d and e), and GR (Figure 3.2c, d and e) catalyzed both GSH- and 
N3GSH -containing substrates with the similar values of Km and Kcat. This shows that the 
small size of azide-group could be tolerated not only by Grx1 and GSTO1 that have 
broad substrate specificity, but also by GR that is relatively specific to GSSG. The 
exception was GSTP (Figure 3.1c, d and e), which showed an 8-fold lower catalytic 
efficiency with N3GSH versus GSH. This suggests that GSTP may not catalyze azido-
glutathione efficiently. However, note that there is no direct assay for GSTP-mediated 
glutathionylation, and GSTP assay (1-chloro-2,4-dinitrobenzene alkylation) in this study 
may not represent the reaction of glutathionylation. Overall, these kinetic data supports 
that azido-glutathione detects the reversible change of protein glutathionylation in 
response to ROS. 
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3.2 Clickable glutathione approach in cells 
To extend our data to cardiomyocytes, we applied our clickable glutathione 
approach to a H9c2 myoblast cell line. GS M4 mutant was expressed into differentiated 
H9c2 myocytes by treating with adenovirus containing the GS M4 gene (Ad/GS M4) 
(Figure 3.5a). GS M4 expression did not induce significant cell toxicity or alteration of 
redox systems, such as a thiol-content or levels of redox enzymes in cells (Figure 3.5b 
and c).  
 
 
 
Figure 3.5. A clickable glutathione approach does not induce significant cell 
toxicity or alteration of redox systems. GS M4 mutant was expressed into 
differentiated H9c2 myocytes by treating with adenovirus containing the GS M4 gene. 
(a) Level of GS M4 and other redox enzymes.(b) Cell viability after expression of GS 
M4, determine by trypan blue assay. (c) A total level of thiols in cells after expression of 
GS M4 with incubation of azido-Ala. Cells were lysed by freeze-thawing, and protein-
free lysates were analyzed for a thiol-concentration by a bromobimane assay. Results 
represent the mean ± SD, (n=3). Two-tailed Student’s unpaired t-test with Welch’s 
correction, *p < 0.05 and N.S.= non-significant. 
a b c 
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3.3 Clickable GSH approach in H9C2 myocytes for detection of global protein 
glutathionylation 
Initially, GS M4 mutant was expressed into differentiated H9c2 myocytes by 
treating with adenovirus containing the GS M4 gene (Ad/GS M4). Cells were then 
incubated with azido-Ala for 20 h, and treated with ROS stimuli. After the click reaction 
of lysates with rhodamine-alkyne, in-gel fluorescence analysis showed that global 
glutathionylation were induced by exposure to an increasing concentration of hydrogen 
peroxide (Figure 3.6a), glucose deprivation (Figure 3.6b) and  antimycin A (AMA) 
(Figure 3.6c), which is known to induce mitochondrial ROS173.  
 
 
 
 
Figure 3.6. Clickable GSH approach in H9C2 myocytes for detection of global 
protein glutathionylation in response to hydrogen peroxide, ETC blocker and 
glucose deprivation. A glutathione synthetase mutant (GS M4), which synthesizes 
azido-glutathione (γGlu-Cys-azido-Ala), was expressed in differentiated H9c2 cells. 
After incubation of azido-Ala, cells were subjected to ROS. Glutathionylated proteins in 
a b c 
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lysates were identified after click reaction.In-gel fluorescence detection of 
glutathionylated proteins. H9c2 cells expressing GS M4 were incubated with azido-Ala 
for 20 h and treated with (a) H2O2, (b) AMA and (c) glucose deprivation. Collected 
lysates were then subjected to click reaction with rhodamine-alkyne for fluorescence 
detection. Results represent (n = 3) experiments. 
 
3.4 Identification of individual protein glutathionylation including SMYD2 through 
clickable GSH approach 
Previously, we found that SMYD2 can be glutathionylated in response to glucose 
deprivation in HEK293 cells132. Then, we applied our clickable glutathione approach to a 
H9c2 myoblast cell line, which can be differentiated into a cardiac phenotype, to detect 
SMYD2 glutathionylation in vivo. Initially, GS M4 mutant was expressed into 
differentiated H9c2 myocytes by treating with adenovirus containing the GS M4 gene 
(Ad/GS M4). Cells were then incubated with azido-Ala for 20 h, and treated with ROS 
stimuli. The subsequent pull-down analysis after click reaction of lysates with biotin-
alkyne detected glutathionylation of SMYD2 (Figure 3.7a, b and c). In addition, we also 
detected glutathionylation of other sarcomere-associated proteins, including Hsp90 
(Figure 3.7a, b and c), actin, and myosin heavy chain (MHC) (Figure 3.7c). 
 
 
a c b 
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Figure 3.7. Identification of individual protein glutathionylation including SMYD2 
through Clickable GSH approach. Identification of individual glutathionylated proteins 
in response to hydrogen peroxide, ETC blocker and glucose deprivation. H9c2 cells 
expressing GS M4 were incubated with azido-Ala for 20 h and treated with (a) H2O2, (b) 
glucose deprivation and (c) AMA. Glutathionylated proteins were subjected to click 
reaction with biotin-alkyne and pull-downs with streptavidin-agarose, and detected by 
Western blotting with individual antibodies, including SMYD2, Hsp90, actin, and myosin-
heavy chain (MHC). Results represent (n = 3) experiments. 
 
3.5 The level of SMYD2 glutathionylation in H9c2 myocytes 
To estimate the level of glutathionylation on SMYD2, lysates were subjected to 
click reaction with 2 kD-polyethyleneglycol-alkyne (PEG-alkyne), which will increase the 
molecular mass of SMYD2. The subsequent Western blotting analysis found that over 
30% of SMYD2 was glutathionylated upon treatment of AMA for 12 h (Figure 3.8a and 
b). In the same condition, we did not detect any significant signal for irreversible 
oxidation of SMYD2, such as sulfonic acid formation (Figure 3.8c and d). Overall, these 
data support that SMYD2 is susceptible to glutathionylation in response to ROS.  
 
 
 
 
a b 
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Figure 3.8. The level of SMYD2 glutathionylation in vivo. Lysates were subjected to 
click reaction with 2-kD PEG-alkyne. (a and b)The mass shift of SMYD2 was analyzed 
by Western blotting. Detection of SMYD2 oxidations by antibodies that detect sulfonic 
acid. (c)H9c2 cells expressing SMYD2 WT or C13S were treated with AMA, and the 
sulfonic acid formation in SMYD2 was probed by Western blotting after pull-down of 
SMYD2. (d)Validation of the antibody for detection of sulfonic acid. To purified SMYD2 
was added H2O2 (10 mM) without or with pre-treatment of iodoacetamide (I-AM) that 
blocks Cys residues. Blots are the representative of at least two replicates. Results 
represent (n = 3) experiments. 
 
3.6 SMYD2 Cys 13 is a potential candidate for glutathionylation  
SMYD2 has 17 cysteine residues, ten of which are bound to three zinc ions in the 
MYND and Post-SET domains (Figure 3.9a)174. SMYD2 structural data (PDB: 3RIB) 
showed that Cys13 is highly exposed at the protein surface and is surrounded by four 
basic Arg or Lys residues (Figure 3.9a, right), which may increase its potential reactivity. 
Cys13 is in the SET-domain (Figure 3.9a, green) and it is close to a S-
adenosylmethionine (SAM) binding site (Figure 3.9a). Cys13 in SMYD2 is not 
c d 
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conserved among members of the SMYD2 family (Figure 3.9b), but found in its 
orthologs (Figure 3.9c). 
 
 
 
 
 
 
Figure 3.9. SMYD2 Cys 13 is a potential site of glutathionylation (a) The structure 
(PDB: 3RIB) and domains of SMYD2, and an enlarged area around Cys13 in SMYD2. 
(b) Sequence alignment around Cys13 of SMYD2 with other members of the SMYD 
family. (c)The sequence alignment of SMYD2 Cys 13 in SMYD2 orthologs. 
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3.7 SMYD2 is selectively glutathionylated at Cys13  
To determine whether Cys13 is important for SMYD2 glutathionylation, we 
purified wild-type (WT) and C13S mutant proteins of SMYD2 (Figure 3.10b), and 
evaluated their glutathionylation with azido-glutathione in vitro.  
 
 
Figure 3.10. Cysteine 13 is important for SMYD2 glutathionylation (b)Purified 
SMYD2 WT or C13S was mixed with azido-glutathione in vitro, and treated with H2O2 or 
diamide for 15 min. SMYD2 glutathionylation was detected by fluorescence (a and c) or 
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a mass shift (d-f) after click reaction with rhodamine-alkyne or 2-kD PEG-alkyne, 
respectively. Results represent (n = 3) experiments. 
 
 
Notably, after click reaction with rhodamine-alkyne, in-gel fluorescence analysis 
showed that SMYD2 WT was strongly glutathionylated upon addition of H2O2 or diamide 
(Figure 3.10a and c), whereas SMYD2 C13S showed weak signals (Figure 3.10c). In 
addition, the same result was observed when a click reaction was done with 2-kD PEG-
alkyne, showing one Cys modification with SMYD2 WT versus no modification with 
SMYD2 C13S (Figure 3.10d, e and f).  
 
 
Figure 3.11. Selective glutathionylation of SMYD2 Cys 13 position. (a-c) 
Quantifying the molar ratio of rhodamine to SMYD2 concentrations after incubation of 
SMYD2 with oxidized azido-glutathione (N3GSSGN3) and click reaction with rhodamine-
alkyne. Results represent (n = 3) experiments. 
 
a 
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Furthermore, the level of glutathionylation was quantified by measuring the molar 
ratio of rhodamine to SMYD2 concentrations after click reaction with rhodamine-alkyne 
(Figure 3.11a, b and c). Incubation of SMYD2 with oxidized azido-glutathione 
(N3GSSGN3) led to an approximately 1:1 molar ratio of rhodamine to SMYD2 (Figure 
3.11b, blue). In contrast, almost no modification was observed with SMYD2 C13S 
(Figure 3.11b, red), showing the selective glutathionylation at Cys13 of SMYD2.  
 
 
a 
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Figure 3.12. Identification of SMYD2 glutathionylation site by a mass analysis. (a) A 
scheme for mass identification of glutathionylated peptides in SMYD2. SMYD2 glutathionylated 
by azido-glutathione was subjected to click reaction with biotin-DDE-alkyne (click chemistry 
tools, Inc.), which is cleavable by hydrazine, and digested by trypsin at 37°C overnight. Digested 
peptides were incubated with streptavidin-agarose for 3 h, and bound peptides were eluted by 
2% hydrazine in PBS (pH 7.4) for 30 min (twice). The collected sample was ziptiped and 
analyzed for MALDI-TOF and TOF/TOF. (b) The spectrum of MALDI-TOF/TOF with identified 
ions, and the predicted mass table for individual ions. Identified y and b ions are highlighted by 
red and blue colors. The modification on Cys was calculated as 415.14, which adds the mass of 
azido-glutathione and a fragment cleaved from biotin-DDE-alkyne. 
 
. 
3.8 Confirmation of SMYD2 Cys 13 glutathionylation by mass spectrometry. 
 
To directly confirm the modification site, we analyzed glutathionylated SMYD2 by 
mass spectrometry analysis: SMYD2 was glutathionylated by N3GSSGN3 and 
conjugated with biotin-alkyne by click reaction and digested by trypsin. The 
glutathionylated peptides were purified by streptavidin-beads (Figure 3.12a).  
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Figure 3.13. LC-MS/MS (ESI) analysis of glutathionylated SMYD2. Glutathionylated 
SMYD2 was analyzed by ESI LC-MS/MS after the same procedure described in (Figure 
10a), except glutathionylation was induced by addition of diamide (100 µM) in the 
presence of azido-glutathione, detecting the peptides glutathionylated at (a) Cys13, 
(b)Cys74, and (c)Cys321. 
 
MALIDI analysis of eluted samples found one peak that is in precise agreement 
with the molecular weight of the peptide glutathionylated at Cys13 (m/z 1053.5, 
FC*SPGK) (Figure 3.12b and Figure 3.13a). LC-MS/MS analysis confirmed this 
assignment and found two additional peptides glutathionylated at Cys74 (Figure 3.13b) 
and Cys321 (Figure 3.13c).  
3.9 Evaluation of SMYD2 Cys13 glutathionylation in cells 
Glutathionylation of SMYD2 at Cys13 was further confirmed in differentiated 
H9c2 cells (Figure 3.14a) and HEK293 cells (Figure 11b) expressing GS M4. In 
response to AMA with glucose deprivation128, SMYD2 WT was strongly glutathionylated 
while glutathionylation was significantly decreased with SMYD2 C13S. Taken together, 
our data strongly support that SMYD2 is selectively glutathionylated at Cys13.   
 
 
Figure 3.14. Detection of SMYD2 Cys13 glutathionylation in differentiated H9c2 
and HEK293 cells expressing GS M4. (a, b) After transfection of SMYD2 WT or C13S, 
a b 
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cells were incubated with azido-Ala. After inducing glutathionylation, collected lysates 
were subjected to click reaction with biotin-alkyne before pull-downs with streptavidin-
agarose and Western blotting. Results represent (n = 3) experiments. 
 
3.10 SMYD2 Cys13 glutathionylation decreases cell viability  
 Despite a dispensable role of SMYD2 in normal heart development175, we 
hypothesized that SMYD2 may have an important role in muscle under stressed 
conditions. To examine the functional significance of SMYD2 Cys13 glutathionylation, 
we compared cell viability of H9c2 myoblasts following expression of SMYD2 WT 
versus C13S, differentiation to a cardiomyocyte phenotype, and subsequent exposure 
to various ROS stimuli (Figure 3.15a, b, c and d).  
After differentiation, SMYD2 levels were similar in the two cohorts of cells 
expressing SMYD2 WT or C13S within 1.7-fold of the endogenous level (Figure 3.15a). 
Sarcomeric α-actinin was also expressed in a similar level (Figure 3.15b). Differentiated 
H9c2 cells were then treated with H2O2 (25 µM), AMA (2 µg/mL), a nitric oxide donor 
(NONOate, 100 µM), or angiotensin II (1 µM) (Figure 3.15b and d). Under unstressed 
conditions, viability was comparable in cells expressing SMYD2 WT or C13S (Figure 
3.15d, bars 1-2 and 11-12). However, in all stressed conditions, viability was 
significantly decreased in cells expressing SMYD2 WT versus C13S (Figure 3.15d, bars 
3-10), suggesting that SMYD2 Cys13 glutathionylation decreases cell viability.  
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Figure 3.15. SMYD2 Cys13 glutathionylation decreases cell viability. (a) Levels of 
SMYD2 WT and C13S in differentiated H9c2 cells. (b) Protein levels of SMYD2 and α-
actinin in H9c2 myocytes after differentiation. SMYD2 WT or C13S plasmids were 
electroporated to H9c2 myoblasts. Cells were then differentiated for 5 days. After 
differentiation, cells were lysed for comparing the protein levels by Western blotting. (c 
and d) Viability of differentiated H9c2 cells expressing SMYD2 WT or C13S after 
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exposure to H2O2 (25 µM), AMA, (2 µg/mL), angiotensin II (Ag II, 1 µM), or a nitric oxide 
(NO) donor (NONOate, 100 µM) for 24 h. Results represent the mean ± SD, (n = 3). 
Two-tailed Student’s unpaired t-test with Welch’s correction, *p < 0.05  
 
 
To corroborate these findings, we examined cell viability after SMYD2 
overexpression or knockdown. There is no difference of cell viability in an unstressed 
condition after SMYD2 overexpression (Figure 3.16a, bars 1 vs. 2). However, SMYD2 
overexpression rescued viability of cells treated with AMA in a modest but statistically 
significant level (Figure 3.16a, bars 3 vs. 4). Conversely, in an unstressed condition 
(without AMA), there is a modest reduction of cell viability after SMYD2 knockdown 
(Figure 3.16b, bars 1 vs. 3). However, SMYD2 knockdown induced more significant 
reduction of cell viability after treatment of AMA (Figure 3.16b, bars 2 vs. 4). Overall, 
these results support the hypothesis that SMYD2 plays a protective role under cellular 
stress, and SMYD2 Cys13 glutathionylation in response to ROS decreases viability of 
H9c2 cells.  
3.11SMYD2 Cys13 glutathionylation induces a loss of myofibril integrity 
 Because SMYD2 is reportedly involved in sarcomere stabilization176, we 
proposed that the reduced cell viability may be associated with altered sarcomere 
stability upon SMYD2 glutathionylation. To monitor myofibril structure under stress, we 
examined rat neonatal cardiomyocytes treated with AMA. Immunostaining of titin, with 
antibody that binds to the N-terminal region of titin (α-titin-NT) (Figure 3.17a), showed a 
parallel array of striated myofibrils in unstressed cardiomyocytes (Figure 3.17b, top left). 
The directionality analysis showed uniform orientation of myofibrils (Figure 3.18a) 
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Figure 3.16. Correlation between SMYD2 protein level and viability of H9c2 
myocytes ubnder stress conditions. (a and b) Viability of differentiated H9c2 cells 
with overexpression (a) or knockdown (b) of SMYD2 after treatment of AMA (2 µg/mL) 
for 24 h. Results represent the mean ± SD, (n = 3). Two-tailed Student’s unpaired t-test 
with Welch’s correction, *p < 0.05  
 
In contrast, upon incubation of AMA, myofibrils are highly misaligned with a 
complete loss of directionality (Figure 3.17a, bottom left). The directionality analysis 
confirmed the same result (Figure 3.18a), showing a loss of myofibrillar structural 
 
b 
a 
92 
 
integrity. Immunostaining of SMYD2, which binds to the N2A domain of titin, showed the 
same pattern while showing high levels of co-localization with titin (Figure 3.17a, right).  
 
 
 
Figure 3.17. Antimycine A treatment induces a loss of myofibril integrity in rat 
neonatal cardiomyocytes. (a) Localization of SMYD2 and titin antibodies on 
sarcomere. (b) Monitoring the myofibril alignment in rat neonatal cardiomyocytes upon 
incubation of AMA (2 µg/mL) for 12 h. Immunostainings were done by using antibodies 
to SMYD2 (green) titin (α-titin-NT, red). About 30 cells were photographed and 
examined for myofibril alignment or directionality by using ImageJ software. Images 
represent the major myofibril structure in individual conditions. Scale bars, 10 µm. 
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Figure 3.18. Analyses of directionality of myofibrils. Rat neonatal cardiomyocytes 
without expression of SMYD2 (a), or with expression of SMYD2 WT (b) or C13S (c) 
were treated with AMA for 12 h. About 30 cells were photographed and analyzed for 
orientation of myofibrils by ImageJ program. Images are representatives of cells in 
individual conditions. Cells were counted as ‘aligned’ when ‘orientation in degree’ stays 
between -20 to 20 with a ‘distribution of orientation’ more than 10,000.Scale bars, 10 
µm. 
 
3.12 SMYD2 C13S recovers myofibril integrity under oxidative stressed 
conditions. 
To examine the importance of SMYD2 Cys13 glutathionylation for myofibrillar 
structure, we repeated experiments upon expression of SMYD2 WT or C13S to rat 
neonatal cardiomyocytes. Without treatment of AMA, both cells expressing SMYD2 WT 
or C13S showed parallel striated myofibrils stained by titin or HA antibodies (Figure 
3.19a, top rows,). The directionality analysis showed uniform orientation of myofibrils 
(Figure 3.19b and c) (Figure 3.19b, bars 3 and 5, n = 30, triplicate). However, after 
incubation of AMA for 12 h, cells with SMYD2 WT showed disoriented and misaligned 
myofibrils (Figure 3.19b, bottom, columns 1-2). The directionality analysis confirmed the 
same result (Figure 3.19b). Strikingly, cells with SMYD2 C13S retained parallel and 
regular arrangement of myofibrils in a similar pattern to that seen in the unstressed 
condition (Figure 3.19c) (Figure 3.19a, bottom, columns 3-4). Directionality analyses of 
myofibrils in individual cells showed that treatment of AMA induced misaligned 
myofibrils in a high number of cells expressing SMYD2 WT versus a low number of cells 
with SMYD2 C13S (Figure 3.19b bars 4 vs 6, cells with aligned myofibrils: 36.7 ± 3.3% 
vs 63.3 ± 3.3% for SMYD2 WT and C13S respectively, n = 30 cells, triplicate,).  
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Figure 3.19. SMYD2 Cys13 glutathionylation induces a loss of myofibril integrity. 
Monitoring the myofibril alignment in rat neonatal cardiomyocytes upon incubation of 
AMA (2 µg/mL) for 12h: (a) ectopic expression of SMYD2 WT or C13S. 
Immunostainings were done by using antibodies to HA (green) and titin (α-titin-NT, red). 
About 30 cells were photographed and examined for myofibril alignment or directionality 
by using ImageJ software. Images represent the major myofibril structure in individual 
conditions. Scale bars, 10 µm. (b) The percentage of cells that have a parallel array of 
myofibrils in cardiomyocytes. Results represent the mean ± SD, (n = 3). Two-tailed 
Student’s unpaired t-test with Welch’s correction, *p < 0.05  
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Figure 3.20. Fluorescence imaging of sarcomeric proteins in differentiated H9c2 
cells expressing SMYD2 WT or C13S. (a) After co-expression of SMYD2 WT or C13S 
with EGFP-actin or mCherry-myosin to H9c2 cells, cells were differentiated. Cells were 
then treated with antimycin A (AMA) for 12 h. H9c2 cells expressing SMYD2 WT or 
C13S were imaged by EGFP-actin, mCherry-myosin, or α-actinin immunostaining. 
About 30 cells were photographed and examined for directionality of labeled or stained 
proteins by using ImageJ software. (b) The percentage of cells that showed a parallel 
array of labelled or stained proteins. Results represent the mean ± SD, (n = 3). Two-
tailed Student’s unpaired t-test with Welch’s correction, *p < 0.05. Scale bars, 20 µm. 
 
 
In a similar manner, we also examined the structural integrity of differentiated 
H9c2 cells by fluorescence imaging of EGFP-actin, mCherry-MHC, and α-actinin 
immunostaining. All analyses showed the same pattern that upon treatment of AMA, 
cells expressing SMYD2 WT showed a loss of structural integrity, whereas cells with 
SMYD2 C13S maintained the similar structural integrity to ones in the unstressed 
condition (Figure 3.20a and b). Overall, these data support the concept that SMYD2 
Cys13 glutathionylation is responsible for misalignment or destabilization of myofibrils. 
3.13 SMYD2 Cys13 glutathionylation leads to degradation of sarcomeric proteins 
 The loss of stability or integrity of myofibrils is likely due to degradation of 
sarcomeric proteins. Therefore, we compared protein levels in H9c2 myocytes (Figure 
3.21a) and HL-1 cardiomyocytes (Figure 3.21b) expressing SMYD2 WT versus C13S. 
Before treatment with AMA, the protein level of α-actinin was similar in differentiated 
H9c2 cells and HL-1 cardiomyocytes expressing SMYD2 WT or C13S. Exposure to 
AMA resulted in a decreased level of α-actinin and troponin I in cells with SMYD2 WT 
(Figure 3.21a, lane 1 vs. 2) (Figure 3.21b, lane 1 vs. 2), but had no effect in cells with 
SMYD2 C13S (Figure 3.21a, lane 3 vs. 4) (Figure 3.21b, lane 3 vs. 4). Under the same 
condition, treatment with AMA had no effect on the expression levels of actin, MHC, 
SMYD2, and Hsp90 in cells with SMYD2 WT or C13S (Figure 3.21a). Interestingly, we 
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also found that cardiac ankyrin repeat protein (CARP), transcription cofactor that is 
involved in muscle remodeling177, is highly elevated in cells with SMYD2 WT versus 
C13S (Figure 3.21c).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21. SMYD2 Cys13 glutathionylation leads to degradation of sarcomeric 
proteins. (a and b) Sarcomeric protein levels in H9c2 myocytes and HL-1 
cardiomyocytes in response to AMA. H9c2 and HL-1 cells expressing SMYD2 WT or 
C13S were treated with AMA (2 µg/mL) for 12 h. Protein levels were determine by 
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Western blotting. (c) The level of CARP in differentiated H9c2 cells in response to AMA 
treatment. After incubation of AMA for 12 h, lysates were analyzed by Western blotting. 
Results represent the mean ± SD, (n = 3). Two-tailed Student’s unpaired t-test with 
Welch’s correction, *p < 0.05  
 
In addition, we probed the cleavage or degradation of titin by dot-blot analysis: 
the blot was probed with α-titin-NT antibody, which recognizes an N-terminal region of 
titin, after pull-down of titin with α-titin-CT antibody, which binds to a C-terminal region of 
titin (Figure 3.22a). 
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Fgure 3.22. SMYD2 Cys13 glutathionylation leads to degradation or cleavage of 
titin protein. (a and b) Dot blot analysis of titin. To monitor the cleavage or degradation 
of titin, titin was pull-downed with antibody that binds to a C-terminal region of titin (α-
titin-CT), followed by Western blotting with antibody that binds to an N-terminal region of 
titin (α-titin-NT). (c) Localization of titin antibodies on sarcomere. (d)Validation of titin 
antibody (α-Titin-NT). α-Titin-NT antibody recognizes the N-terminus of an I-band region 
(Ig7-8) of titin. Immunostaining of rat neonatal cardiomyocytes (top) or isolated 
myofibrils (from mouse gastrocnemius) (bottom) with α-titin-NT antibody shows a high 
co-localization pattern with α-actinin antibody that stains the Z-disk of sarcomere. (d) 
Validation of titin antibody (α-titin-CT). α-Titin-CT antibody recognizes the C-terminal 
region of titin. Immunostaining of isolated myofibrils (from mouse gastrocnemius) with α-
titin-NT and α-titin-CT shows the alternating staining pattern. Results represent the 
mean ± SD, (n = 3). Two-tailed Student’s unpaired t-test with Welch’s correction, *p < 
0.05  
 
Upon treatment of AMA, the level of titin detected by α-titin-NT was decreased in 
cells expressing SMYD2 WT (Figure 3.22a, lane 1 vs. 2), whereas it was unchanged in 
cells expressing SMYD2 C13S (Figure 3.22a, lane 3 vs. 4). In addition to H9c2 cells, we 
also examined HL-1 mouse cardiac muscle cells upon ectopic expression of SMYD2 
WT or C13S. Similarly, reduced levels of titin was observed in cells expressing SMYD2 
WT (Figure 3.22b, lane 1 vs. 2), whereas no changes were observed in cells with 
SMYD2 C13S (Figure 3.22b, lane 3 vs. 4).  
  
 
 
Figure 3.23. SMYD2 knockdown induces more significant reduction of α-actinin 
and troponin I. Sarcomeric protein levels in response to AMA after SMYD2 
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knockdown. Results represent the mean ± SD, (n = 3). Two-tailed Student’s unpaired t-
test with Welch’s correction, *p < 0.05  
 
Supporting these findings, without treatment of AMA, levels of α-actinin or 
troponin I remain similar upon SMYD2 knockdown (Figure 3.23, lane 1 vs. 3). However, 
SMYD2 knockdown induced more significant reduction of α-actinin and troponin I levels 
upon treatment of AMA (Figure 3.23, lane 2 vs. 4), which correlates with the data that 
SMYD2 knockdown induces more significant reduction of cell viability upon incubation 
of AMA. These data support that SMYD2 Cys13 glutathionylation leads to reduced 
levels of several sarcomeric proteins, such as α-actinin, troponin I, and titin.   
 
 
 
Figure 3.24. Proteases responsible for sarcomeric protein degradation.  MMP-2 
and calpain 1 are localized on sarcomere. 
 
3.14 MMP-2 and calpain 1 are responsible for sarcomeric protein degradation 
under stressed conditions 
Previously, calpain 1/3 and MMP-2 have been found to play a role in degradation 
of sarcomeric proteins, including α-actinin and titin (Figure 3.24). Therefore, we 
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evaluated whether calpain and MMP-2 contribute to sarcomeric protein degradation in 
our model. The decreased levels of α-actinin and troponin I in the presence of AMA was 
restored upon incubation with an MMP-2 inhibitor (ARP-100) (Figure 3.25a, lane 2 vs. 4) 
or MMP-2 knockdown (Figure 3.25b, lane 2 vs. 4), while there was no effect on the 
expression levels of other proteins, including actin and SMYD2 (Figure 3.25a).   
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Figure 3.25. SMYD2 C13S is protective against sarcomeric proteins degradation 
and cell death in oxidatively stressed conditions. Sarcomeric protein levels in 
response to AMA after incubation of ARP-100 (MMP-2 inhibitor) (d), or MMP-2 
knockdown (e). (f-g) The cell viability in response to AMA after incubation of ARP-100 
(1 µM) or calpastatin (calpain 1 inhibitor, 5 µM) (f) or MMP-2 knockdown (g). In all 
conditions, differentiated H9c2 cells were treated with AMA (2 µg/mL) for 12 h. Lysates 
were analyzed by Western blotting. Cell viability was analyzed by Trypan blue assay. 
Results represent the mean ± SD, (n = 3). Two-tailed Student’s unpaired t-test with 
Welch’s correction, *p < 0.05  
 
 
We further evaluated H9c2 cell viability upon exposure to inhibitors of MMP-2 
(ARP-100) and calpain 1 (acetyl-calpastatin) (Figure 3.25d) or MMP-2 knockdown 
(Figure 3.25c). As expected, viability of H9c2 cells was significantly decreased after 
d 
c 
105 
 
treatment of AMA (Figure 3.25c and d). This effect was mitigated by treatment with 
either the MMP-2 or calpain 1 inhibitor (Figure 3.25d, bars 4 vs. 5 and 6) or MMP-2 
knockdown (Figure 3.25c, bars 2 vs. 4), suggesting that calpain 1 and MMP-2 contribute 
to the stressor-induced reduction of cell viability and degradation of α-actinin and 
troponin I. Overall, these data reveal that SMYD2 C13S is protective against sarcomeric 
proteins degradation and cell death in oxidatively stressed conditions, and that SMYD2 
Cys13 glutathionylation is an important molecular event involved in degradation of 
sarcomeric proteins mediated by MMP-2 and/or calpain-1. 
3.15 Preparation and characterization of glutathionylated SMYD2 
 In myocytes, SMYD2 is involved in mono-methylation of Hsp90, which increases 
Hsp90 chaperone activity. SMYD2 then forms a complex with mono-methylated Hsp90. 
This complex binds to N2A, a domain of titin, which has been implicated to be important 
for sarcomere stabilization.  
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Figure 3.26. Preparation of SMYD2 glutathionylated version to characterize the 
SMYD2:HSP90:N2A interactions (a) A scheme for preparing non-glutathionylated 
SMYD2 (SMYD2-SH) and glutathionylated SMYD2 (SMYD2-SSG). (b) Chromatograms 
of ion-exchange column purification of SMYD2-SH and SMYD2-SSG. (d) Gel analysis 
and purity after purification of SMYD2-SH and SMYD2-SSG. (c) Western blotting that 
shows glutathionylation of SMYD2. 
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Therefore, we investigated whether glutathionylation of SMYD2 changes its 
enzymatic activity or interaction with Hsp90 or the N2A domain. To interrogate the effect 
of glutathionylation on SMYD2 in vitro, purified SMYD2 WT was glutathionylated by 
incubating with oxidized glutathione (GSSG) (Figure 3.26a). Note that similar incubation 
of SMYD2 with oxidized azido-glutathione (N3GSSGN3) induced selective 
glutathionylation of SMYD2 at Cys13. SMYD2 WT (SMYD2-SH) and glutathionylated 
SMYD2 (SMYD2-SSG) were further purified (Figure 3.26b and d). SMYD2-SH and 
SMYD2-SSG show the same partial digestion pattern by trypsin (Figure 3.27), 
suggesting their similarly folded structures.  
 
 
Figure 3.27. Characterization of SMYD2-SH and SMYD2-SSG. The partial trypsin 
digestion of SMYD2-SH and SMYD2-SSG. Purified SMYD2-SH or SMYD2-SSG was 
incubated with trypsin, quenched at the indicated time, and resolved on a SDS-PAGE 
gel. 
 
3.16 SMYD2 glutathionylation does not affect its methyl transferase activity  
 
SMYD2 enzymatic activity was then examined by LC-MS methylation analysis 
(Figure 3.28b). In this assay, when using Hsp90 as a substrate, SAH production was 
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decreased by approximately 50% with SMYD2-SSG versus SMYD2-SH (the rate of 
SAH production: 13.2 ± 1.6 nM min-1 for SMYD2-SH vs. 7.4 ± 1.0 nM min-1 for SMYD2-
SSG) (Figure 3.28b).  
 
 
 
Figure 3.28. Enzyme activity of SMYD2 and glutathionylated SMYD2. (a) A scheme 
of protein methyl transferase reaction catalyzes by SMYD2 and  utilization of SAM as 
d c 
b 
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the methyl donor while production of SAH as the byproduct. The amount of SAH was 
quantified by comparing to the amount of deuterium-labelled SAH (SAH-D4) as an 
internal standard in LC-MS analysis. (b and c) Enzyme activity of SMYD2-SH or 
SMYD2-SSG with Hsp90 (b) or 11-mer p53 peptide (HSSHLKSKKGQ) (c) as 
substrates. SMYD2-SH or SMYD2-SSG (200 nM) was mixed with Hsp90 (4 µM) or p53 
peptide (25 µM) and SAM (25 µM) in TBST (pH 7.4). The SAH formation was quantified 
in a time-dependent manner. (d) Enzyme activity of SMYD2 with different substrates. 
SMYD2 (200 nM) was mixed with GST-Hsp90, N2A, or GST (all 4 µM). (e) Enzyme 
activity of SMYD2 (WT, C13S and C13D) with Hsp90 as a substrate. Results represent 
the mean ± SD, (n = 3). Two-tailed Student’s unpaired t-test with Welch’s correction, *p 
< 0.05  
 
In comparison, when p53 peptide was used as a substrate, SAH production was 
less significantly decreased with SMYD2-SSG versus SMYD2-SH (Figure 3.28c). A 
decrease of Hsp90 methylation, but not p53 methylation, with SMYD2-SSG suggests 
that the complex formation between Hsp90 and SMYD2 may be disrupted upon SMYD2 
glutathionylation.  
 
 
Figure 3.29.  SMYD2 glutathionylation does not change methylation levels of 
Hsp90 in cells, and SMYD2 enzyme activity is not responsible for degradation of 
sarcomeric proteins.  (a) Levels of mono-methyl lysine (Me-Lys) in Hsp90 in cells in 
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response to AMA. After incubation of AMA to differentiated H9c2 cells for 12 h, Hsp90 
was immunoprecipitated and probed for its level of Me-Lys. There is no change of 
methylation levels in Hsp90 upon incubation of AMA (lane 1 vs. 2), whereas SMYD2 
knockdown decreases Hsp90 methylation level (lane 1-2 vs. 3-4). (b) Valuation of an 
antibody to Me-Lys. Purified Hsp90 was methylated by incubation of SMYD2 and SAM, 
detecting methylation of Hsp90. (c) SMYD2 enzyme activity is not necessary for 
degradation of sarcomeric proteins. Differentiated H9c2 cells expressing SMYD2 WT 
and catalytically inactive mutants (Y1240F) were treated with AMA for 12 h. The level of 
α-actinin was analyzed by Western blotting, showing no difference between 
enzymatically active SMYD2 and inactive SMYD2.   
 
Despite the modest reduction of SMYD2 enzymatic activity upon glutathionylation 
in vitro, the level of Hsp90 methylation was unchanged in cells upon treatment of AMA 
(Figure 3.29a), suggesting a low or no change of SMYD2 enzyme activity upon 
glutathionylation. Importantly, a catalytic inactive SMYD2 Y240F mutant could also lead 
to degradation of α-actinin in the same manner to SMYD2 WT (Figure 3.29c), 
suggesting that SMYD2 enzyme activity is not responsible for sarcomeric protein 
degradation.   
3.17 SMYD2 Cys13 glutathionylation induces dissociation of SMYD2 from N2A 
and Hsp90 
Next, we analyzed whether SMYD2-Hsp90-N2A interactions can be disrupted 
upon SMYD2 glutathionylation. A binding assay showed that GST-Hsp90 binds to 
SMYD2-SH more strongly than SMYD2-SSG (Figure 3.30b), showing that SMYD2 
glutathionylation decreases the SMYD2-Hsp90 interaction. This result was further 
confirmed by co-immunoprecipitation (co-IP) in HEK293 cells expressing SMYD2 WT or 
C13S (Figure 3.30c): SMYD2 WT binding with Hsp90 was significantly decreased in 
stressed conditions (AMA and glucose deprivation) (Figure 3.30c, lane 1 vs. 2). In 
contrast, SMYD2 C13S interaction with Hsp90 did not change in identical stressed 
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conditions (Figure 3.30c, lane 3 vs.4). Similarly, the N2A domain was examined for 
binding with SMYD2 (Figure 3.30d and e). 
 
 
 
 
a 
c b 
e d 
112 
 
Figure 3.30. SMYD2 Cys13 glutathionylation induces dissociation of SMYD2 from 
N2A and Hsp90. (a) GST, GST-N2A, and GST-Hsp90 were expressed in E. coli and 
purified by affinity-column (glutathione-agarose). (b and c) SMYD2 glutathionylation 
disrupts its interaction with Hsp90. (b) Purified SMYD2-SH and SMYD2-SSG were 
incubated with GST-Hsp90 bound to glutathione beads, and eluted sample was 
analyzed. (c) Hsp90 was co-immunoprecipitated with SMYD2 WT or C13S from 
HEK293 cells in response to AMA with glucose deprivation. (d and e) SMYD2 
glutathionylation disrupts its interaction with N2A. (d) Purified SMYD2-SH and SMYD2-
SSG were incubated with GST-N2A bound to glutathione beads, and eluted sample was 
analyzed. (e) FLAG-N2A was co-immunoprecipitated with SMYD2 WT or C13S in 
HEK293 cells in response to AMA with glucose deprivation. 
 
N2A binding to SMYD2 was decreased with SMYD2-SSG versus SMYD2-SH 
(Figure 3.30d). Similarly, co-IP confirmed that SMYD2 WT lost its interaction with N2A 
in the presence of stressors (Figure 3.30e, lane 3 vs. 4) while SMYD2 C13S retained its 
interaction (Figure 3.30e, lane 1 vs. 2).  
3.18 SMYD2 Cys13 glutathionylation induces dissociation of SMYD2 from titin in 
rat neonatal cardiomyocytes. 
To further demonstrate that SMYD2 dissociates from the N2A domain or titin 
upon SMYD2 glutathionylation, we examined co-localization of SMYD2 and titin in the 
sarcomeres of rat neonatal cardiomyocytes expressing SMYD2 WT or C13S. 
Consistently, immunostaining showed high levels of SMYD2 co-localized with titin in the 
absence of AMA (Figure 3.31a). However, co-localization of SMYD2 with titin was 
decreased upon incubation of AMA (Figure 3.31a, and 3.31d, n = 30, Pearson 
Coefficient 0.80 ± 0.03 and 0.32 ± 0.04 without and with AMA, respectively). Notably, 
co-localization of SMYD2 with titin was also decreased in cells expressing SMYD2 WT 
after incubation of AMA (Figure 3.31b and 3.31d, n = 30, Pearson Coefficient 0.75 ± 
0.05 and 0.43 ± 0.04 without and with AMA, respectively), whereas co-localization 
remains high in cells expressing SMYD2 C13S (Figure 3.31c and 3.31d, n = 30) 
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Pearson Coefficient 0.77 ± 0.05 and 0.67 ± 0.06 without and with AMA, respectively). 
 
 
Figure 3.31. Co-localization of titin and SMYD2 decreases upon incubation of 
AMA in rat neonatal cardiomyocytes expressing SMYD2 WT versus C13S. (a-
c)Immunostainings of cardiomyocytes with antibodies to titin (α-titin-NT, red), HA, or 
 
 
b 
c d 
a 
114 
 
SMYD2 (green) are shown with enlarged areas for details (the red boxes). (d)Pearson’s 
correlation coefficients were calculated to estimate co-localization of titin and SMYD2. 
Images represent the major co-localization pattern in individual experiments. Scale 
bars, 10 µm. Results represent the mean ± SD, (n = 3). Two-tailed Student’s unpaired t-
test with Welch’s correction, *p < 0.05. 
  
Taken together, these data provide evidence that SMYD2 Cys13 
glutathionylation disrupts the SMYD2 interaction with Hsp90 and N2A of titin, and 
induces dissociation of SMYD2 from titin and the sarcomere. 
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Figure 3.32. SMYD2 C13D mutation retains the interaction with Hsp90 and N2A. 
(a) A rationale for expressing SMYD2 C13D: The size and charge of Asp are similar to 
ones of oxidative cysteine modifications, such as sulfinic acid. (b) Gel analysis of 
SMYD2 C13D after purification. (c-d) Purified SMYD2 WT and C13D were incubated 
with GST-Hsp90 (c) or GST-N2A (d) bound to glutathione beads, and eluted samples 
were analyzed by Coomassie stains. (e) SMYD2 C13D mutant retains the interaction 
with Hsp90 and N2A. Hsp90 or FLAG-N2A was co-immunoprecipitated with SMYD2 WT 
or C13D from HEK293 cells. 
 
3.19 SMYD2 C13D mutation doesn’t affect its HSP90 or N2A interactions 
 
In addition to glutathionylation, cysteine oxidation in proteins involves formation 
of sulfenic acid, sulfinic acid, and sulfonic acid, which are relatively smaller size 
modifications in comparison to glutathionylation (Figure 3.32a). Although we did not 
detect sulfonic acid formation in SMYD2, we examined potential effects of these 
oxidations on the interaction of SMYD2 with Hsp90 and N2A. To mimic a small size 
oxidative modification in SMYD2 at Cys13, we expressed SMYD2 C13D in which Asp 
serves as a close mimic of sulfinic acid at Cys13 with respect to both size and charge 
(Figure 3.32a).  
In vitro binding assays showed that similar levels of SMYD2 WT and C13D were 
bound to Hsp90 and N2A (Figure 3.32c and d). Co-IP experiments confirmed these 
results, showing that SMYD2 WT and C13D maintain the similar level of binding with 
both Hsp90 and N2A (Figure 3.32e). These data suggest that glutathionylation of 
SMYD2, rather than small size oxidative modifications, is likely responsible for 
disrupting SMYD2 interactions with Hsp90 and N2A. 
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3.20 Dissociation between SMYD2 and N2A leads to degradation of sarcomeric 
proteins 
3.20.1 SMYD2 C13S protects N2A from MMP-2 mediated degradation 
Next, we attempted to examine whether the dissociation between SMYD2 and 
N2A is responsible for sarcomere degradation. We hypothesized that the N2A domain 
or its proximal region in titin may contain the cleavage sites of MMP-2 or calpain-1, 
which could be protected when SMYD2 binds to N2A, whereas the SMYD2-N2A 
dissociation may expose N2A for degradation.  
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Figure 3.32. Predicted N2A cleavage sites by MMP2 protease. The potential 
cleavage site(s) were predicted by using the MMP cleavage site prediction tool 
(CleavPredict). (a) N2A sub-domains (I80-UN2A-I81-I82-I83, Ig: Immunoglobulin 
domain; UN2A: a unique sequence in N2A) with potential cleavage sites that have a 
high score of probability. The potential cleavage sequences are shown with their 
positions in N2A indicated by arrow head. (b) The peptide sequence of N2A. N2A sub-
domains are shown in different colors, and the MMP-2 cleavage sites with a high score 
are shown in box. (c) The potential MMP2 cleavage site with different scores and the 
resulting mass after cleavage. These are results from the MMP cleavage site prediction 
tool (CleavPredict). (d) Gel analysis of N2A degradation upon incubation of MMP-2 with 
an increasing amount of MMP-2. The blot is a representative of at least three replicates. 
 
 
Notably, several domains of titin in the I-band of sarcomere, which can be 
unfolded during contraction and relaxation, were suggested to contain MMP-2 cleavage 
sites. However, it is unknown whether N2A contains the cleavage site. The N2A domain 
is composed of four immunoglobulin domains (Ig80-83) and a unique sequence region, 
called N2A-Us (also called UN2A), between Ig80 and Ig81 (Figure 3.32a).  
 
 
 
 
Figure 3.33. Dissociation between SMYD2 and N2A leads to degradation of 
sarcomeric proteins by MMP-2. N2A is degraded by MMP-2, and SMYD2 protects 
a b 
c 
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N2A from degradation. Purified N2A was incubated with active MMP-2 in (a)a time-
dependent manner  or (b) with an increasing amount of SMYD2 . (c) Binding of SMYD2 
protects the N2A domain from MMP-2 degradtion.  
 
We analyzed whether N2A contains the MMP-2 cleavage site by using the MMP 
cleavage site prediction tool (CleavPredict). The tool predicted the presence of several 
MMP-2 cleavage sequences in N2A, including high probability of cleavage sites around   
N2A-Us (Figure 3.32b and c).  
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Figure 3.34. Predicted N2A cleavage sites by calpain 1. The potential cleavage 
site(s) were predicted by using the calpain cleavage site prediction tool (LabCas). (a) 
N2A sub-domains (I80-UN2A-I81-I82-I83, Ig: Immunoglobulin domain; UN2A: a unique 
sequence in N2A) with potential cleavage sites that have a high score of probability. 
The potential cleavage sequences are shown with their positions in N2A indicated by 
arrow head. (b) The peptide sequence of N2A. N2A sub-domains are shown in different 
colors, and the relevant calpain 1 cleavage sites are shown in a box. (c) The potential 
calpain 1 cleavage site with different scores and the resulting mass after cleavage. (d) 
Gel analysis of N2A degradation upon incubation of calpain 1 with an increasing amount 
of calpain 1. (e) Gel analysis of N2A degradation by MMP-2 or calpain 1 in the same 
gel, which shows the similar size of cleaved products. SMYD2 is not degraded by MMP-
2 or calpain 1. Blots are representative of at least three replicates. 
 
Indeed, purified N2A was cleaved upon incubation with active MMP-2 (Figure 
3.32d and 3.33a). The sizes of the cleaved products (~approximately 50kD and 35kD) 
appear to correlate with the potential cleavage in domains around N2A-Us. Notably, 
addition of SMYD2 C13S, which binds to the N2A domain, decreased degradation of 
N2A by MMP-2 in a dose-dependent manner (Figure 3.33b).  
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Figure 3.35. Dissociation between SMYD2 and N2A leads to degradation of 
sarcomeric proteins by calpain1. N2A is degraded by calpain 1, and SMYD2 protects 
N2A from degradation. Purified N2A was incubated with calpain 1 in (a) a time-
dependent manner or (b) with an increasing amount of SMYD2. (c) Binding of SMYD2 
protects the N2A domain from MMP-2 degradtion. Data are representative of at least 4 
independent experiments.  
 
3.20.2 SMYD2 C13S protects N2A from calpain 1 mediated degradation 
Similarly, N2A was predicted to have the calpain 1 cleavage site (Figure 3.34a, b 
and c). N2A was also susceptible to degradation by calpain 1 (Figure 3.34d and Figure 
3.35a). Incubation with SMYD2 C13S protected N2A degradation from calpain 1 (Figure 
3.35b). Interestingly, both MMP-2 and calpain 1 resulted in cleaved products of N2A 
that are of similar sizes (Figure 3.35e), suggesting that N2A has a local motif vulnerable 
to degradation by both proteases.  
3.20.3 SMYD2 C13S protects titin in myofibrils from MMP-2 mediated degradation 
To further support our hypothesis, we performed the similar experiments in which 
N2A was replaced by myofibrils isolated from mouse gastrocnemius muscle that has an 
N2A-titin isoform (Figure 3.36a). Incubation of fresh myofibrils with active MMP-2 
induced degradation of titin, decreasing the level of N2A-titin (T1) while increasing the 
level of T2 (Figure 3.36b), a degraded product of titin165 (Figure 3.36c, lane 2 vs. 3, and 
34d). Notably, incubation of SMYD2 protected titin from MMP-2 mediated degradation 
(Figure 3.36c, lane 3 vs. 4, and 34d). Titin degradation was also inhibited upon an 
addition of ARP-100 (Figure 3.36c, lane 3 vs. 5, and 34d). In these experiments, there 
was no apparent degradation of MHC (Figure 3.36c). These data support our model that 
the SMYD2 binding interaction with N2A, titin, or sarcomeric proteins confers the 
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protection against proteases, whereas SMYD2 dissociation upon glutathionylation 
contributes to degradation of sarcomeric proteins (Figure 4.1) 
 
 
 
 
 
Figure 3.36. Titin in isolated myofibrils is degraded by MMP-2, and SMYD2 
protects titin from degradation. (a) Titin N2A isoform (b) Titin degradation product T2. 
(c) Myofibrils isolated from mouse gastrocnemius muscle were incubated with active 
MMP-2 in the absence and presence of SMYD2. Extracts of soleus muscle and left 
d c 
b a 
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ventricle (LV) isolated from 6.5-months old rat were used as standards (lane 1 and lane 
6) to show the position of N2A-titin or N2B-titin isoforms, respectively. (d) Levels of titin 
degradation by measuring the ratio of T1 or T2 to MHC. Results represent the mean ± 
SD, (n = 3). Two-tailed Student’s unpaired t-test with Welch’s correction, *p < 0.05  
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CHAPTER 4: DISCUSSION 
 
The detrimental role of ROS in cardiac muscle has been extensively analyzed in 
ischemia-reperfusion injuries that are well-known to cause a burst of mitochondrial ROS 
and contribute to muscle damage.178 One direct effect of ROS in muscle is the reduction 
of myofilament contraction, which is attributed to alteration in calcium transient, reduced 
calcium sensitivity of myofilament, or reduced maximal peak force of myofilament 
contraction.143-145 Many of these ROS effects partially result from oxidative modifications 
of sarcomeric or myofibrillar proteins.138, 140, 141, 179, 180 For example, ROS elevated 
during ischemic reperfusion cause glutathionylation and carbonylation of actin,138 
glutathionylation of troponin subunits,139 and disulfide formation in tropomyosin,140 
nitration of myosin,141 many of which result in the reduced contractile force of 
myofilaments. Titin is also oxidized in multiple regions. For example, the N2B domain of 
titin forms disulfide, which increases muscle stiffness.142 The cryptic cysteine residues in 
Ig-domains of titin at the I-band are also glutathionylated, which reduces passive 
stiffness.123  The detrimental role of ROS in cardiac muscle has been extensively 
analyzed in ischemia-reperfusion injuries that are well-known to cause a burst of 
mitochondrial ROS and contribute to muscle damage.178 One direct effect of ROS in 
muscle is the reduction of myofilament contraction, which is attributed to alteration in 
calcium transient, reduced calcium sensitivity of myofilament, or reduced maximal peak 
force of myofilament contraction.143-145 Many of these ROS effects partially result from 
oxidative modifications of sarcomeric or myofibrillar proteins. 
 
124 
 
 
 
Figure 4.1. A proposed mechanism of sarcomere destabilization upon SMYD2 
glutathionylation. Under unstressed conditions, SMYD2-Hsp90 binds with and 
protects N2A in titin from MMP2 or calpain 1 mediated degradation (top). Under 
stressed conditions, SMYD2 is glutathionylated and dissociated from N2A or titin, 
allowing for sarcomeric protein degradation (bottom).  
 
For example, ROS elevated during ischemic reperfusion cause glutathionylation 
and carbonylation of actin,138 glutathionylation of troponin subunits,139 and disulfide 
formation in tropomyosin,140 nitration of myosin,141 many of which result in the reduced 
contractile force of myofilaments. Titin is also oxidized in multiple regions. For example, 
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the N2B domain of titin forms disulfide, which increases muscle stiffness.142 The cryptic 
cysteine residues in Ig-domains of titin at the I-band are also glutathionylated, which 
reduces passive stiffness.123   
In addition to reduction of myofilament contraction, numerous data support that 
cellular stress during ischemic-reperfusion or nutrient starvation causes proteolysis of 
sarcomeric and myofibrillar proteins,181, 182 which eventually causes reduced muscle 
mass and a loss of contractility. There is emerging evidence that the highly ordered 
structure of sarcomere is maintained in a dynamic process that involves an intricate 
balance between assembly and degradation of sarcomeric proteins by the action of 
many chaperones and proteases.183 While proteolytic systems, including the ubiquitin-
proteasome system (UPS) and calpains, are largely responsible for sarcomeric and 
myofibrillar protein degradation,183 the molecular link between sarcomeric protein 
oxidative modification and the action of the protease system is not well-characterized. In 
this report, we showed that glutathionylation of sarcomere-associated SMYD2 serves as 
a potential mechanism of ROS that contributes to degradation of sarcomeric proteins. 
 Glutathionylation plays an important role in regulating protein function in cellular 
stress.127 In this report, we used our clickable glutathione approach to detect 
glutathionylation of multiple proteins, including SMYD2, under stressed conditions. A 
key idea of our approach is routing glutathione biosynthesis to clickable glutathione by 
using a mutant of a glutathione biosynthetic enzyme.147 An azide-tag on glutathione can 
be replaced by other bioorthogonal functional groups, including terminal-alkene.129 A 
modified clickable glutathione is an efficient substrate of glutathione disulfide reductase 
(GR) (Figure 3.2), glutaredoxin 1 (Grx1) (Figure 3.3), glutathione transferase omega 
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(GSTO) (Figure 3.4), and is tolerated in cells without significant disturbance of the redox 
system (Figure 3.5),129, 148 all of which support that our approach is suitable for 
investigating glutathionylation in response to cellular stress.  
 We confirmed glutathionylation of SMYD2 in various stressed conditions (Figure 
3.7) and found selective glutathionylation at Cys13 (Figure 3.10, 3.11, 3.12 and 3.14). 
While there are 17 Cys residues in SMYD2, many of them are bound to zinc atoms or 
buried inside SMYD2, thus may not be accessible for glutathionylation. In our 
experiments, we did not detect sulfonic acid formation in SMYD2 (Figure 3.8). However, 
other oxoforms, such as sulfenic acid, may form. It is also possible to form Cys 
modifications with other electrophiles, such as 4-hydroxynonenal184 and fumarate,185 
which may induce a similar cellular phenotype to glutathionylation, due to their relatively 
large size. 
 A key observation in our report is that myofibril integrity is significantly lost in cells 
expressing SMYD2 WT in response to ROS, whereas SMYD2 C13S protects myofibrils 
from degradation (Figure 3.19 and 3.20), showing a critical role of SMYD2 
glutathionylation in myofibril integrity or sarcomere stability. While our data may suggest 
a pathologic consequence of SMYD2 glutathionylation in muscle, sarcomere 
degradation or disassembly is not only found in pathologic conditions, such as 
cardiomyopathy186 and chronic hibernating cardiomyocytes.187 Sarcomere degradation 
is also observed in physiologic processes during muscle growth or remodeling that 
requires a partial degradation of sarcomeres or myofibrils in order to form a higher mass 
of muscle.188 Indeed, the beneficial role of sarcomere proteolysis is well-recognized in 
skeletal muscle growth and stress adaptation.188 It is notable that SMYD2 expression is 
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peaked in fetus and neonates, but reduced in adult mice.175 In addition, during fetal and 
neonatal periods, N2BA titin that contains N2A is abundant in cardiomyocytes, while it 
decreases in adult cardiomyocytes.189 Therefore, it is interesting to correlate that both 
N2BA titin and SMYD2, which are implicated in sarcomere degradation in our study, are 
abundant in fetal and neonatal cardiomyocytes in which sarcomeres are more dynamic 
during developmental growth and remodeling.190 More importantly, N2BA titin and fetal 
genes increase in cardiac diseases,191, 192 while SMYD2 expression may be induced 
under stress.193 Therefore, it will be interesting to investigate SMYD2 expression and its 
glutathionylation in pathological conditions in future studies. 
 Another important finding is that protein interaction between SMYD2 and the N2A 
domain of titin contributes to modulating myofibril or sarcomere degradation (Figure 
3.21 and 3.22). Indeed, protein-protein interactions at titin’s extensible domains, 
including N2B, PEVK, and N2A at the I-band, plays a central role in stress-signaling.149 
For example, the N2B domain has four Ig-domains and one extensible unique sequence 
region (N2B-Us). A small chaperone, αB-crystallin, binds to N2B-Us for stabilization or 
protection of sarcomere from stress.150 N2B-Us also interacts with signaling complexes, 
including four-and-a-half-LIM-domain protein (FHL2) that can translocate to the nucleus 
to participate in gene expression.149 Similarly, N2A has four Ig-domains and one 
extensible unique sequence (N2A-Us). Hsp90-SMYD2 chaperone complex binds to 
N2A, mainly with N2A-Us.176 Our data showed that the SMYD2-N2A interaction protects 
N2A from degradation by MMP-2 and calpain 1 (Figure 3.34 and 3.35), and SMYD2 
also protect titin in myofibrils from MMP-2 mediated cleavage (Figure 3.36). Therefore, 
our data support the concept that N2A is an important domain of titin where the SMYD2-
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Hsp90 chaperone complex interacts for stabilization or protection of sarcomeres (Figure 
3.31). Notably, it is interesting to find that N2A can be cleaved by MMP-2 and calpain 1 
in our data (Figure 3.34 and 3.35). While titin is known to be degraded by MMP-2 and 
calpain 1,165, 194 the exact cleavage sites of titin are unknown and difficult to confirm due 
to a large size of titin (>3 MD). Our data suggest that titin can be cleaved at the N2A 
domain that interacts with SMYD2.  
While our data support the importance of SMYD2-N2A dissociation for myofibril 
disassembly, the results may explain a part of the complex mechanisms by which 
SMYD2 glutathionylation contributes to sarcomere degradation. Notably, N2A-Us also 
interacts with CARP,195 which acts as a transducer that translocate to the nucleus 
during mechanical stress and is upregulated in ischemic-reperfusion injury or nutrition 
starvation.195 Our data showed that CARP is up-regulated under stress in cells with 
SMYD2 WT versus C13S (Figure 3.21), suggesting that SMYD2 glutathionylation is in 
part responsible for stabilization of CARP. Because CARP is implicated in activating or 
suppressing many fetal genes involved in muscle remodeling, it will be interesting to find 
which genes are modulated upon SMYD2 glutathionylation.  
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 Reactive oxygen species (ROS) are important signaling molecules that contribute 
to the etiology of multiple muscle-related diseases, including cardiomyopathy and heart 
failure. There is emerging evidence that cellular stress can lead to destabilization of 
sarcomeres, the contractile unit of muscle. However, it is not completely understood 
how cellular stress or ROS induce structural destabilization of sarcomeres or myofibrils. 
Protein glutathionylation is one of the major protein cysteine oxidative modifications that 
play an important role in redox signaling and oxidative stress. In this report, we used a 
clickable glutathione approach in a cardiomyocyte cell line, and found that SET and 
MYND Domain Containing 2 (SMYD2), lysine methyltransferase, can be selectively 
glutathionylated at Cys13. Functional studies showed that SMYD2 Cys13 
glutathionylation serve as a key molecular event that leads to a loss of myofibril integrity 
and degradation of sarcomeric proteins mediated by matrix metalloprotease 2 (MMP-2) 
and calpain 1. Biochemical analysis demonstrated that SMYD2 glutathionylated at 
Cys13 loses its interaction with Hsp90 and N2A, a domain of titin that is important for 
167 
 
stress-sensing. Upon dissociation from SMYD2, N2A or titin was susceptible to 
degradation by MMP-2, suggesting a protective role of SMYD2 in sarcomere stability. 
Taken together, our results identify SMYD2 glutathionylation as a novel molecular 
mechanism by which ROS contribute to sarcomere destabilization and potentially 
muscle dysfunction. 
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